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 Imaging of biological tissue in a relevant environment is critical to accurately 
assessing the effectiveness of chemotherapeutic agents in combatting cancer.  Though 
many three-dimensional (3D) culture models exist, conventional in vitro assays continue 
to use two-dimensional (2D) cultures because of the difficulty in imaging through deep 
tissue.  3D tomographic imaging techniques exist and are being used in the development 
of 3D efficacy assays.  However, most of these assays look at therapy endpoint (dead or 
living cancer cell count) and do not capture the dynamics of tissue response. 
 Biodynamic imaging (BDI) is a 3D tomographic imaging and assay technique that 
uses the dynamics of scattered coherent light, or speckle, to measure dynamic response of 
tissue to perturbations.  Dynamic measurements allow BDI to not only assess overall 
efficacy, but to also measure phenotypic changes in cancer tissue as it responds to 
therapy.  Because BDI captures the phenotypic response of tissue, it naturally accounts 
for genetic and microenvironmetal factors, and shows promise as an accurate predictor of 




 This thesis presents the development of BDI into a predictive assay for assisting 
in chemotherapy selection.  It shows how microenvironmental factors alter BDI response 
measurements.  It reports how different BDI biomarkers can accurately assess sensitivity 
to platinum treatment in xenograpft models of ovarian cancer.  Changes in sensitivity 
during metastasis are observed, and a method for addressing sample variability and 
heterogeneity is presented.  A predictive model for chemotherapeutic selection is 
developed and applied retrospectively to primary esophageal cancer.  Finally, a new 
imaging modality called tissue dynamic spectroscopic imaging (TDSI) is presented, 






CHAPTER 1. BYODYNAMIC IMAGING (BDI) 
1.1 Introduction 
Biodynamic imaging is a full-frame, coherent imaging and drug response assay 
technique that uses biological motion as both contrast agent and information source.  It 
achieves a high imaging rate without the need for biological stains or other labels, 
preserving the natural chemical and physiological state of imaged tissue.  Biodynamic 
imaging has been used to study the effect of chemotherapeutics on ex vivo and in vitro 
cancer tumor models [1-3], the viability of oocytes for artificial insemination [4, 5], and 
is currently developing predictive methods for assisting in cancer patient chemotherapy 
selection [6].   
Biodynamic imaging currently has three modes: optical coherence imaging (OCI), 
motility contrast imaging (MCI), and tissue dynamics spectroscopy (TDS).  Biodynamic 
imaging begins with optical coherence imaging (OCI) [7], a full-frame, en face optical 
coherence tomographic technique with important similarities to optical coherence 
tomography (OCT) [8-12].  Motility contrast imaging (MCI) [13] uses intensity 
fluctuations in the OCI image as the contrast agent of an imaged tissue target.  These 
intensity fluctuations arise due to dynamic changes in the local index of refraction of the 
target volume.  Thus, MCI generates a representation of the motile activity of the target 




spectral power of the intensity fluctuations of the OCI image.  The shape of the resulting 
power spectrum characterizes the motion present within the imaged volume and changes 
with changing tissue behavior.  Thus TDS measures the response behavior of tissue to 
perturbations, such as chemotherapeutics. 
This thesis presents the development of BDI toward being a clinically relevant 
predictive assay for chemotherapeutic therapy selection.  CHAPTER 2 reports a study of 
how changes in the cellular microenvironment affect BDI response measurements and 
shows distinct differences in behavior between 2D cell culture and 3D tissue 
environments.  It presents a 3D tissue model that mimics 2D culture response and shows 
that this model will transition into the full 3D culture response.  An assay of ovarian 
cancer sensitivity to platinum therapies using BDI is presented in CHAPTER 3, while 
CHAPTER 4 looks at how metastasis alters that sensitivity.  This is the first application 
of BDI to in vivo and ex vivo chemotherapeutic response assessment. BDI shows clear 
differences in ex vivo response between tumor biopsies grown from sensitive and 
insensitive ovarian cancer cell lines.  A method for assessing in vivo response using ex 
vivo re-exposure is discussed, and a method for predicting patient response to 
chemotherapy is developed using BDI measurement biomarkers. 
CHAPTER 5 presents the development of a fourth BDI mode: tissue dynamics 
spectroscopic imaging (TDSI), which combines the biodynamic measurements of OCI, 
MCI, and TDS as contrast agent to generate a false color image of the spatially 
heterogeneous behavior of a tissue sample, including response to chemotherapeutics.  




cancer tissue that are not apparent in traditional BDI analysis.  Such heterogeneous 
response to chemotherapeutics has important implications determining the cause of multi-
drug resistance and patient relapse. 
 
1.2 Cellular dynamics and 3D tissue 
Imaging of live tissue in a three-dimensional (3D) environment is of critical 
importance to biophysical science and especially to the study and treatment of cancer.  
Several 3D tumor models have been developed, including in vitro multicellular tumor 
spheroid models [15-18] and murine xenografts.  However, the majority of 
chemotherapeutic efficacy assays continue to use two-dimensional (2D) culture models.  
This is because photon diffusion makes direct optical imaging through highly scattering 
media, such as tumor tissue, difficult and limits the depth resolution of traditional 
microscopy.   
 Cells have a typical size of 5-20 μm, which is much larger than the wavelength of 
near-infrared light.  In this regime, ray optics dominates and cells act as tiny lenses.  
Stacked into tissue structures, these lenses generate a “showerglass” effect due to optical 
aberrations that limits resolution as imaging depth increases.  Furthermore, the eukaryotic 
cell is a heterogeneous body containing many different structures with different refractive 
indices.  This causes significant scattering of light as it propagates through tissue. 
 Eukaryotic cell structure can be separated into different regions.  Outside the cell 
is the extracellular matrix, a region composed of collagen proteins and other molecules 
used by to organize cells into tissue.  The cell membrane surrounds the interior of the cell.  




extracellular matrix, communicates with other cells via cell-cell contacts, and takes in 
nutrients and expels waste.  The cytoskeleton, made of microtubules, actin filaments, and 
stress fibers, is a flexible structure with high tensile strength that gives the cell dynamic 
rigidity.  The cytoplasm fills the interstices of the cytoskeleton and is made up of cellular 
organelles, the largest of which, the nucleus, exhibits both geometric optic and Mie 
scattering behaviors [19].  Other organelles important to the study of tissue imaging are 
mitochondria (typical size: 200 nm to 5 μm), endosomes and exosomes.  For these 
smaller organelles, scattering dominates optical interaction.  
Cells and organelles are in constant motion.  Mitosis and other processes change 
cell shape and cause undulations in the cell membrane. The common characteristic 
frequency of these undulations is in the range of 0.01 Hz to 0.1 Hz [20, 21].  Cytoskeletal 
components are in dynamic equilibrium, constantly being built and dismantled.  
Organelles driven by molecular motors travel at speeds in the range of several microns 
per second [22-25].  The various cellular components create dynamically shifting 
scattering interfaces. 
 
1.3 Dynamic Light Scattering 
When tissue is illuminated with a coherent source, scattering interactions lead to 
coherent noise, or speckle.  Speckle arises due to interference between multiple waves 
scattered from spatially distributed variations in the refractive index of the illuminated 




cellular and tissue components.  These components are in motion and generate time-
varying speckle patterns through dynamic light scattering.  This dynamic speckle is used 
by BDI to assess tissue health and response to perturbations. 
Dynamic light scattering is a well-established technique for investigating 
biological systems, and has been used to study motions of the cell and nucleus [27, 28].  
Dynamic light scattering is appropriate for optical systems in the dilute limit where single 
scattering interactions dominate.  Diffusing wave spectroscopy (DWS), first proposed by 
Pine, et al. in 1988 [29], extends dynamic light scattering to optically dense scattering 
regimes by using the diffusion approximation to treat photon scattering as random walks 
[30, 31]. 
Dynamic light scattering is caused by the change in the optical phase of the 
scattered light as the particle moves.  For instance, consider the incident light scattering 
off a moving particle illustrated in Figure 1.1 [26]. 
 
 







The light field scattered from a single moving particle is 
  1.1 
As the position  of the particle changes, the phase of the scattered light changes.  The 
difference in phase from one position to the next is 
  1.2 
where  is the scattering vector.  The direction of the initial k-
vector defines , and the magnitude of q for a scattering angle θ is 
  1.3 
Field autocorrelation is obtained by taking an ensemble average over scattered 
fields, or by integrating over all time.  (Ensemble averages and time averages are 
equivalent under stationary statistics.)  The stochastic sum is evaluated using a 
probability distribution as 
  1.4 
where  is the probability functional of the displacement Δx.  The 
autocorrelation is  
  1.5 
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and the stochastic sum is equivalent to an integral over the probability distribution 
  1.6 
where the autocorrelation is proportional to the Fourier transform of the probability 
functional.  The physical process, such as diffusion or drift or active transport, determines 
this probability functional.  Different types of motion have different probability 
functionals. For diffusion, the probability functional is 
 1.7 
which gives the diffusion autocorrelation function 
  1.8 
A one-dimensional random walk can be described as the sum of uncorrelated steps Xi  
  1.9 
where N is the number of steps, Xi is a Gaussian distributed set of random steps, and Z is 
evaluated as statistical ensembles [4].  Active transport is defined by velocity 
distributions and by persistence times (the time of unidirectional free runs).  If the 
velocity distribution is Gaussian, and the mean free run time (persistence time) 
distribution is exponential, then the rms step size is given by
  1.10 
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where it is assumed that the mean speed is zero, with a standard deviation given by the 
characteristic speed v0 with a characteristic persistence time τ.  The expectation of the 
squared displacement of the random walk is then 
  1.11 
The mean number of steps taken in a measurement time t is given by , which 
yields 
  1.12 
where the equivalent diffusion coefficient of the actively driven random walk is defined 
as 
  1.13 
The holographic fringes and the dynamic speckle set the resolution of the speckle 
image.  Nyquist theory predicts that two pixels are required to fully resolve each 
interference fringe and two fringes resolve each speckle.  In practice, however, it is more 
convenient to use the “Rule of 9” with three fringes per speckle and 3 pixels per fringe.  
The holographic fringe spacing is set by the angle  between the beam axis of the off-
axis reference beam and the optic axis of the speckle.  The fringe spacing is 
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and the resolution of the system is 
  1.15 
where N is the number of pixels on the CCD and FOV is the field-of-view of the 
reconstruction. 
  
1.4 Optical Coherence Imaging (OCI) 
Tomographic techniques have successfully imaged through deep tissue and have 
found wide clinical and experimental applications. Ultrasound [32], X-ray computed 
tomography (CT) [33], and magnetic resonance imaging (MRI) [34] are standard imaging 
modalities found in hospitals all over the world.  In more recent years, confocal 
microscopy [35-37], photoacoustic tomography (PAT) [38-43], and optical coherence 
tomography (OCT) [8, 10, 11] have achieved smaller resolutions and are growing in 
clinical use [44-47]. 
OCT is based on low-coherence reflectometry [48], an optical ranging technique 
that measures reflectance as a function of depth.  OCT uses heterodyne detection to 
obtain a one-dimensional A-scan of the reflectance.  When combined with a second, 
transverse OCT scan, a two-dimensional B-scan image is generated.  The joint system 
rasters across the target to construct the full 3D image.  Depth resolution is limited by the 
coherence-length of the source independent of the numerical aperture of the imaging 




endoscope.  OCT has gained wide acceptance since it was first reported in 1991 [8].  It 
has a penetration depth of about 1 mm in turbid media and a spatial resolution near the 
diffraction limit for shallow depths in translucent media.  
In 1996, Dr. David Nolte’s group, in collaboration with Dr. Paul French of 
Imperial College, London, invented holographic optical coherence imaging (OCI) [49] as 
a full-frame imaging version of optical coherence tomography (OCT) for probing tissue 
up to a millimeter in depth.  In OCI, positioning the reference off-axis relative to the 
optical axis of the scattered photons creates a spatially modulated intensity profile.  The 
off-axis orientation allows OCI to record the full image frame in a single capture.  OCI 
was first performed using photorefractive quantum well (PRQW) devices to image live 
rat osteogenic tumor spheroids [50, 51].  Dr. Kwan Jeong updated the OCI system by 
moving the PRQW device from image plane to Fourier plane and, later, by replacing the 
PRQW device with a digital CCD camera [52-54].  Current OCI uses low-coherence [55-
58] digital holography [59] to reduce background and improve sensitivity.  It achieves 
high frame rates (25 frames per second) while maintaining resolution and has proven to 
be a useful tool for studying tissue-level biophysics. 
 
1.4.1 Fourier-domain digital holography 
At the core of the OCI is Fourier-domain digital holography. The theory is 
explained in greater detail in [7, 54]. In brief, consider the Mach-Zehnder interferometer 






Figure 1.2. Fourier-domain digital holographic configuration. A beam splitter (BS) splits 
the light into two coherent beams: the object beam that impinges on the target, and the 
reference beam that is routed through a series of delay mirrors (M). Light scattered from 
the target (OP) is projected onto the Fourier plane (FP) by the lens (L) where it is 
spatially heterodyned with the reference beam, and the CCD records the resulting 
interference as an intensity hologram. The hologram is numerically Fourier-transformed 
back into an image (IP) of the target. 
 
A beam splitter splits the coherent light wave into two waves: a reference plane wave and 
an object wave. The object wave  scatters off a target and is Fourier-transformed 
by an ideal lens of focal length  onto the plane of the CCD camera. The object wave at 
the plane of the detector is given by  




where  is the wavelength of the source.  The reference wave travels through the delay 
path and is directed onto the detector so that at the detector.  The reference plane-wave is 
given by 
  1.17 
where  and  are the spatial wavenumbers.  The reference wave in OCI replaces the 
need for a phase modulator in conventional OCT, and an off-axis configuration provides 
a spatially modulated carrier wave, which allows for full-frame imaging of the hologram.  
The electric wave at the detector is a coherent sum of the object and reference waves. The 
intensity pattern recorded by the detector is 
  1.18 
The first two terms of Eq. (1.18) are the respective intensities of the object and 
reference beams at the detector. The last two terms are Fourier- and conjugate Fourier-
transforms of the image. After capturing the intensity pattern using a digital camera, a 
computer performs numerical reconstruction of the images using a fast Fourier transform 
(FFT).  The third and fourth terms can be calculated using Eq. (1.16) and Eq. (1.17), and 
are given by  
  1.19 
and 




The image is located at (  and the conjugate image is located at 
, and are separated from the zero-order image at (0,0).  Figure 1.3 shows 
an example of recorded Fourier-domain hologram and the resulting reconstructed image. 
 
 
Figure 1.3. OCI frame and corresponding transformed image. a) The OCI Fourier frame 
captures b) a holographic intensity pattern when the optical path length difference 
between the object and reference beams is within the coherence length of the source. c) 
The corresponding image and conjugate image are reconstructed from the OCI frame 
through a fast Fourier transform. d) An image of the target, a tumor spheroid, can be seen. 
 
For a CCD camera with pixel size  and a chip size of N by N pixels, 
the resulting reconstructed image has N by N pixels of size  




where  is the width of the CCD chip.  Fourier detection is less sensitive than 
image detection to debris in the light path, and digital processing improves image contrast 
and noise reduction capabilities. Holographic image capture also provides depth 
resolution when a low-coherence illumination source is used. 
 
1.4.2 Three-dimensional volumetric holography with low-coherence 
Imaging through translucent, dynamic media is complicated for a source with 
high-coherence because photons coherent at the detector have scattered from different 
depths within the sample, Depth resolution can be achieved by using a low-coherence 
source to generate the holograms [55]. With a low-coherence source, only photons whose 
distance-of-flight is equal to that of the reference interfere coherently at the plane of the 
detector to generate the hologram. In the backscatter configuration, the depth resolution is 
given by [60] 
 1.22
where  is the full-width-half-max (FWHM) bandwidth of the source.  Scattered light 
outside this volume is added incoherently and can be removed during image processing. 
This coherence-gating allows for images to be made of specific depths within the target, 






1.5 The OCI system 
Figure 1.4 shows a complete diagram of the current OCI system. A neutral 
density filter (ND) attenuates the light from the super-luminescent diode (SLD).  The 
waveplate (λ/2) adjusts the polarization of the beam before it is split by a polarizing 
beamsplitter (PBS) into object and reference beams to maximize the intensity of the 
object beam. The object beam is focused by lens L1 onto the target, and the scattered 
light is collected and projected onto an image plane (IP) by lenses L2 (f = 15 cm) and L3 
(f = 15 cm).  The projected image plane is Fourier-transformed by lens L4 (f = 5 cm) onto 
the second Fourier-plane (FP2) at the camera (CCD) with a 1/3 magnification. The 
reference beam passes through the delay stage (dotted box) and is attenuated by another 
ND to match the intensity of the object beam at the CCD.  The reference beam is directed 
onto the CCD by means of mirrors (M). Lenses L5 and L6 are used to shape the reference 
beam to match the beam profile of the scattered object beam at the CCD. Interference 
patterns are recorded and digitally Fourier-transformed back to the image plane to 
generate OCI images of the target. The delay stage can be adjusted to probe different 






Figure 1.4. BDI setup. 
 
Short coherence light at 847.2 nm wavelength with 50 nm FWHM bandwidth is 
supplied by a 20.5 mW Superlum Broadlighters Fiber Lightsource (model: S-840-B-I-20 
SM).  This gives a depth resolution of 6.3 μm (single-scattering).  The CCD camera is a 
Rolera EM-C2 from QImaging with a bit depth of 14 bits.  Recorded images are 800 by 
800 pixels with a square pixel of size of 8 μm.  This results in a minimum practical fringe 
spacing of 24 μm and a minimum speckle size of 72 μm.  Capture is triggered externally 
through a function generator controlled by a custom-developed LabVIEW VI (National 




beam delay stage.  Camera frames are recorded using StreamPix 5 (Norpix).  Spatial 
coordinates and zero-path matched position of the reference beam delay stage are 
recorded for each tumor [61]. 
 
1.6 Motility Contrast Imaging (MCI) 
Motility contrast imaging (MCI) [13] uses the speckle intensity fluctuations as a 
label-free image contrast to create a false-color image of the sample motility.  Sample 
motility is influenced by all cellular activity and is an indication of cell health and 
cellular action.  MCI images can indicate regions of hypoxia/necrosis and other tumor 
inhomogeneities that exhibit strong motional differences.  
A sequence of OCI frames is captured, representing one observation of the living 
target.  By capturing several sequences, changes in the time-dependent behavior of the 
target are detected.  For a single OCI sequence, the temporal normalized standard 
deviation (NSD) of the intensity I is defined at each pixel (x,y) as 
  1.23 
This value is used to assign a color to each pixel to create a false-color MCI frame of the 
motility of the sample during that sequence.  Figure 1.5 shows MCI frames of two 
different HT-29 tumor spheroids following the application of either growth medium or 
nocodazole (10 μg/mL).  The motility of the sample changes very little after the growth 






Figure 1.5. MCI frames of healthy and treated HT-29 tumor spheroids at successive times. 
Frames show the motility of the spheroid after application of either a) growth medium, in 
the healthy case, or b) 10 μg/mL nocodazole, for the drugged tumor. Motility of the 
healthy tumor is maintained while that of the drugged tumor decreases over time as the 
nocodazole begins to affect cellular processes. MCI frames also show the low-motility 
region that often forms in the interior of the tumor spheroids. 
 
Changes in sample health can be inferred by calculating the average NSD of the 
entire sample during a particular OCI sequence and recording that average over time. 
Figure 1.6 shows the average NSD in time for two different tumor spheroids. One 
spheroid received growth medium at time t = 0 while the other tumor received 10 μg/mL 
nocodazole.  The average sample NSD decreases rapidly following the application of 
nocodazole. The average NSD of the healthy tumor did not change significantly, from 




Figure 1.6. Average NSD of healthy (growth medium) and drugged (nocodazole) tumor.  
The motility of the drugged tumor decreases rapidly following the application of 
nocodazole (10 μg/mL) with a decay time of 33 minutes 
 
MCI and average NSD detect changes in the overall motion of a sample, but these 
changes can arise from several different biological processes. Tissue dynamics 
spectroscopy analyzes the different frequencies of motion within the sample to separate 
one process from another. 
 
1.7 Tissue Dynamics Spectroscopy (TDS) 
Another technique within BDI is tissue dynamics spectroscopy (TDS) [62]. TDS 
uses speckle fluctuation spectroscopy on the reconstructed OCI frames to produce a 
characteristic power spectrum for the sample. The shape of this power spectrum is 
dependent on the motion of scattering objects within the sample and changes with 




Different biological processes happen at characteristic speeds [20, 63, 64]. All 
these processes result in local fluctuations in the index of refraction and cause dynamic 
changes in the scattered speckle. The autocorrelation of the intensity I of a pixel is given 
by 
  1.24 
where τC is the relaxation of the process.  For diffusion, 
  1.25 
with ki being the magnitude of the wavevector of the incident light and D being the 
diffusion coefficient. The autocorrelation can be written as 
  1.26 
The Fourier transform is a Lorentzian  
  1.27 
In log-space, S(ω) has a distinct shape and exhibits a knee frequency 
  1.28 
While the observed process may not be strictly diffusive, the power spectrum can be 
approximated as 
  1.29 
Figure 1.7 shows how the relaxation time of the autocorrelation function influences the 
shape and knee frequency of the power spectrum, and Figure 1.8 shows how s influences 






Figure 1.7. Example autocorrelation functions and power spectrum. a) Three 
autocorrelation plots are shown for three different relaxation times—0.5 s, 1 s, and 2 s—
along with b) their corresponding power spectra.  
 
Figure 1.8. Example power spectra with exponential dependencies. The graph shows 





A tissue sample may exhibit many different biological processes at the same time, 
causing its speckle fluctuation spectrum to have a complicated shape.  Also, detection 
bandwidth causes information above the Nyquist frequency to be shifted to frequencies 
near the Nyquist.  This raises the power spectral density at high frequencies and creates a 
Nyquist floor to which the power spectrum asymptotes.  Figure 1.9 shows the fluctuation 
power spectrum for two different tumor spheroids.  MIA PaCa-2 (PaCa-2) tends to be a 




Figure 1.9. Example power spectra of healthy tumor spheroids for two different cell lines.  
Speckle fluctuation power spectra show the power spectral density for different 
frequencies of motion of scattering objects within the target volume and are characteristic 
of the behavior of the target.  The power spectra are fitted with a modified Lorentzian 
function.  For the HT-29 spectrum, the effective relaxation time τC = 61.3 seconds and the 




By comparing the power spectrum of a sample after a perturbation relative to the 
baseline power spectrum of the sample, the time-dependent response of the sample to the 
perturbation can be determined.  For a power spectrum  measured at time , the 
differential spectral power is defined as 
  1.30 
 
where  is the time of the baseline measurement.  More recently, computations have 
used  
  1.31 
Eq. (1.30) is the first-order term in the Taylor expansion of Eq. (1.31), so in the limit that 
 the two definitions are equal.  However, Eq. (1.31) is less susceptible 
to noise in the spectrum. 
The differential spectral power can be represented by a drug-response 
spectrogram that acts as a “voiceprint” of the sample response to a perturbation. Figure 
1.10 shows example response spectrograms for tumor spheroids of two different cell lines, 
PaCa-2 and HT-29, to nocodazole (10 μg/mL).  Frequency (horizontal axis) spans three 
orders of magnitude from 0.01 Hz to 12.5 Hz.  Time (vertical axis) typically spans 11-16 
hr.  The zero on the time axis marks the introduction of the perturbation (nocodazole in 
Figure 1.10).  
 
D ω ,t( ) = S ω ,t( )− S ω ,t0( )
S ω ,t0( )





Figure 1.10. Example drug response spectrograms to nocodazole (10 μg/mL) for 
spheroids of two different cell lines. The 2D color graph shows shifts in speckle 
fluctuation spectra relative to the baseline sample spectrum. These shifts are indicative of 
changes in the dynamics of the spheroid due to the introduction of the drug. 
 
The amplitude of the differential spectral power is indicated by color.  Shifts to 
higher power are red, indicative of an enhancement of the motions in the target at that 
frequency.  Blue areas mark shifts to lower spectral power and indicate suppression of 
motions at that frequency.  Thus a spectrogram gives an easily readable representation of 
the changes in motion of the imaged volume in response to the perturbation.  In Figure 
1.10, two tumor spheroids from different cancer cell lines, MIA-PaCa-2 (PaCa-2) and 
HT-29, respond to the microtubule-destabilizing drug nocodazole.  As microtubules make 
up part of the cytoskeleton of the cell, the destruction of microtubules leads to less rigid 
structure in PaCa-2 and a corresponding enhancement appears in the low frequencies as 
cell deformation increases.  HT-29 forms a more rigid cell structure (see CHAPTER 2.4) 
and the cell deformations do not appear at frequencies above 0.01 Hz, but the high 
frequency enhancement in the spectrogram indicates increased vesicle activity as the cells 




1.8 Biomarkers and Feature Vectors 
BDI generates a wealth of information that is difficult to quantify objectively.  One 
method developed is to use feature vectors to condense the results from OCI, MCI, and 
TDS into a set of values that characterize a single sample response measurement.  The 
feature vector includes a set of conditional biomarker values calculated from OCI, MCI, 
and TDS measurements of the initial and final condition of the sample.  Examples of such 
markers are backscatter intensity (BB), NSD, spectral knee frequency and slope, and the 
change in these parameters. 
Other biomarker values are obtained through a linear filter applied to the 
spectrogram and integrated over log frequency.  For linear filter , the biomarker 
value M is 
  1.32 
Figure 1.11 shows a collage of different linear filters used to generate biomarker values 





Figure 1.11. Collage of linear biomarker filters. 
 
Other biomarkers come from logical combinations of the linear filters described 
above and select for specific biological responses.  For example, APOP is a nonlinear 
filter that identifies enhanced frequency bands at high and low frequencies (a signature 






CHAPTER 2. CELLULAR ADHESION EFFECTS IN BIODYNAMIC IMAGING 
2.1 Abstract 
In this chapter, biodynamic imaging is used investigate the change in adhesion-
dependent tissue response in 3D cultures.  Cellular adhesions play a role in tissue 
dynamics and have connections to chemotherapeutic resistance and metastasis. The 
results of this study show that increasing density of cellular adhesions slows motion 
inside tissue and alters the response to cytoskeletal drugs.  A clear signature of membrane 
fluctuations was observed in mid frequencies (0.1 – 1 Hz) that was enhanced by the 
application of cytochalasin-D that degrades the actin cortex inside the cell membrane.  
This enhancement feature is only observed in tissues that have formed adhesions, because 
cell pellets initially do not show this signature, but develop this signature only after 
incubation enables adhesions to form. 
 
2.2 Introduction to cellular adhesions 
Traditionally, imaging through deep tissue has been difficult and in vitro tissue 
assays have favored a two-dimensional (2D) culture model. However, while 2D culture 
assays have the advantage of simplicity, 2D monolayer cultures feature an artificial 
environment that modifies cell shape and cell contacts and provides limited connections 




chemical properties of, and the contacts with, the extracellular environment modify 
expression of adhesion compounds and adhesion structure [66-69]. Cellular adhesions 
have been linked to the development and spread of various cancers including colorectal 
[70, 71], breast [72], ovarian [73], and lung [74], and may contribute to the resistance of 
tumors to chemotherapeutic treatments [75, 76]. Cellular adhesions are an important 
target of chemotherapy research. 2D cell cultures, with a modified cellular environment 
and lack of adhesions, may change how they respond to chemotherapeutic drugs. A more 
biologically accurate, three-dimensional (3D) tissue model is needed. 
Multicellular tumor spheroids closely resemble the macrostructure of in vivo 
cancer tumors [77]. Use of dense 3D tissue models such as tumor spheroids for drug 
testing has been limited by the difficulty to obtain information from deep tissue imaging. 
Biodynamic imaging (BDI) makes it possible to probe processes within the tissue without 
altering the surrounding microenvironment. In this chapter, BDI and dynamic light 
scattering (DLS) are used to investigate how culture morphology affects cellular 
adhesions and the measured response of the sample to cytoskeletal drugs. Much of this 
work was reported in [78]. 
 
2.3 Materials and Methods 
2.3.1 Cell cultures 
Cell lines are from American Type Culture Collection (ATCC) Manassas, VA. 
Cells were cultured in their respective growth media (Table 2.1) at 37 °C in a humidified 
CO2 incubator.  All growth media contain 10% fetal calf serum (Atlanta Biologicals), 




Table 2.1. Cell culture information. Information about genetic mutations comes from [79, 
80]. 
Cell Line Cell Origin Mutation Growth Medium 
HT-29 Human colon c-myc, H-ras, K-ras, N-ras, myc, fos and p53 McCoy 5A 
UMR-106 Rat bone p53 DMEM
MIA PaCa-2 Human pancreas p53, K-ras DMEM 
 
2.3.2 Cytoskeletal Drugs 
Cytochalasin-D, colchicine, nocodazole, paclitaxel, and dimethyl sulfoxide 
(DMSO) were obtained from Sigma. Each drug was prepared to twice the desired 
concentration to allow for later mixing inside the sample well [78].  DMSO (0.05%) 
dissolved in growth medium was used as the negative control in all experiments, and all 
drugs were dissolved in DMSO before being added to the growth medium to improve 
solubility. The cytoskeletal action of each drug is outlined in Table 2.2. 
Table 2.2. Cytoskeletal drug information. 
Drug Abbr. Mechanism of Action 
Cytochalasin-D Cyto. Inhibit actin polymerization 
Colchicine Colch. Inhibit microtubule polymerization
Nocodazole Noco. Inhibit microtubule polymerization 
Paclitaxel Taxol Inhibit microtubule depolymerization 
 
 
2.3.3 Tumor Spheroids  
A 50 mL capacity Sythecon rotating bioreactor (Synthecon, Houston, TX) was 




until tumor spheroids were just visible to the naked eye (200-300 μm), before spheroids 
began being used in an experiment [78]. Spheroids typically had diameters between 150 
and 500 μm. Spheroids were immobilized in 8-well chamber slides.  To immobilize the 
spheroids, they were first pipetted into each well. Then 75-100 µL of low gelling 
temperature agarose made up in medium without serum was added. After a gentle mixing 
step some of the mixture was withdrawn to leave approximately 100µL of material. The 
spheroid was typically covered by the agarose. 
Slides were glued to a 2-axis translation stage in the OCI system to prevent the 
sample moving during observation. Eight tumors were selected from each slide for 
testing, typically one tumor from each well. Growth medium was heated to 37 °C and 
pipetted into each well until the well was full and any bubbles were removed. The wells 
were covered with a microscope slide to limit evaporation and contamination from the 
environment. 
 
2.3.4 Cell Suspensions 
Cells were grown in flasks until about 80 % confluent. Cells were then trypsinized 
and pipetted into a 1.5 in. diameter petri dish at 105-106 cells/mL. Low gelling 
temperature agarose was added until the sample was slightly more than 1 mm in depth at 
its center. Cells and agarose were gently mixed and the dish was incubated for ~4 hours 
prior to experimentation. Each sample was cut into roughly rectangular shape (~10 mm x 
5 mm) using a razor blade and then placed inside a flow cell (49IR1, NSG Precision 




37 °C and between 3 and 5 mL were injected through the flow cell using a syringe and 
tubing (Figure 2.1) [78]. 
 
 
Figure 2.1. Flow cell and drug injection components. a) Drug injection components were 
a syringe (3-10 mL volume, depending on need), a needle (20 guage), a pipet tip, ~3 in. 
of 1/32 in. inner diameter flexible tubing, and two ~3 in. pieces of 1/16 in. flexible tubing. 
b) Components were assembled as shown, the cut sample was placed inside the flow cell, 
and the device was clamped to the target stage of the DLS system. 
 
2.3.5 Cell Pellets 
8-well chamber slides of cell pellets were prepared from centrifuged cell cultures 
and embedded in low-temperature gelling agarose. Slides received either no incubation, 
or 24 hours of incubation, prior to testing to allow adhesions to form. Slides of cell pellets 
were otherwise handled in the same manner as those of tumor spheroids [78]. 
 
 
2.3.6 Optical Coherence Imaging (OCI) 
A diagram and explanation of the optical coherence imaging (OCI) system can be 
found in CHAPTER 1.5. OCI frames of each tumor spheroid were captured in cycles 




travel time to allow the system to transition between tumors, followed by frame capture: 
10 background frames captured at 10 frames per second (fps) with the reference beam not 
zero-path matched, then 50 frames at 0.5 fps and 500 frames at 25 fps with the reference 
beam zero-path matched. All frames were captured with a 10 ms exposure time. 
Tumor spheroids were observed for 12 cycles (4.8 hours) to allow the tumors to 
stabilize.  Then half of the growth medium (~0.5 mL) was removed from each well and 
replaced with a control drug. Tumors were then observed for 27 cycles (10.8 hours). 
 
2.3.7 Image-domain DLS  
A diagram of the homodyne DLS system is shown in Figure 2.2 [78]. The 
incident beam at 840 nm wavelength was supplied by a high-coherence 106 mW Melles-
Griot CW diode laser (56DOL817). The CCD camera used was a Retiga EX from 
QImaging. Capture was triggered externally through a function generator controlled by a 
custom developed LabVIEW (National Instruments) program. Camera frames were 
recorded using StreamPix 5 (Norpix). Another custom LabVIEW program controlled the 
pump (NE-500, New Era Pump Systems) used for drug injection. 
Frames were captured in 4-minute cycles, capturing 250 frames at 10 fps followed 
by 100 frames at 0.5 fps. All frames were captured with a 10 ms exposure time. Cells in 
suspension were observed for 46 cycles (~3 hours) to allow the sample to stabilize.  Then 
2 mL of control drug was injected into the flow cell over 8 minutes to completely replace 
the growth medium. Samples were observed for 180 cycles (12 hours). Frame capture 




samples were fixed by injecting 3 % glutaraldehyde into the flow cell and were observed 
for another 16 cycles (~1 hour). 
 
 
Figure 2.2. Image-domain DLS. In image-domain DLS (a), incident light from a CW 
laser scatters off a target and then is collected and projected onto the image-plane (IP) at 
a CCD by lenses (L1 and L2). Focal lengths of the two lenses are 5 mm for L1 and 20 
mm for L2, resulting in a 4x magnification of the object plane at the CCD. The DLS 
frame captures an image of the object (b) as a dynamic speckle pattern. Dynamic 
measurements are made on a small portion of the sample (c), indicated by the white box 
in (b).  
 
2.4 Cell line Trends in Cellular Adhesions 
Three cell lines were chosen to investigate the effects of cell adhesion density on 
the performance of biodynamic imaging [78].  The holographic MCI images (Figure 2.3a) 
of human colorectal adenocarcinoma HT-29 demonstrated the strongest adhesions.  They 
form round spheroids and exhibit a low-motility core indicative of hypoxia even in small 
tumors (< 100 mm).  Human pancreatic carcinoma MIA PaCa-2 (PaCa-2) showed the 
weakest adhesions, forming loose cell conglomerates instead of spheroids with no low-
motility core even in larger tumors (> 300 mm). Rat osteosarcoma UMR-106 had 
adhesion density falling between the other two, forming round spheroids but exhibiting 




Figure 2.3b shows microscope images of cells suspended in agarose for each cell 
line. HT-29 cells formed heterogeneous suspensions composed of cell clumps and 
individual cells. UMR-106 and PaCa-2 formed fairly homogenous suspensions. PaCa-2 
formed slightly larger cell clumps due to rapid cell growth. 
 
 
Figure 2.3. Holographic motility contrast images (MCI) (a) showing the shape and 
motility of tumor spheroids of different sizes for three cell lines along with microscope 
images (b) of cell suspensions for the same cell lines. The white bars in MCI are 200 μm. 
HT-29 formed tight, round tumor spheroids with large regions of low motility in the 
center even in tumors of less than 200 μm diameter.  UMR-106 formed round tumor 
spheroids, with low-motility central regions typically appearing in spheroids of greater 
than 200 μm diameter.  PaCa-2 formed irregularly shaped tumors that showed no low-
motility regions even at sizes greater than 500 μm. 
Sample responses were measured under the four cytoskeletal drugs (Table 2.2). 
Figure 2.4 shows average tissue response spectrograms for the three cell lines under the 




in the mid-frequencies, generally between 0.1 and 1 Hz (shown in white square on the 
figure).  This frequency band is associated with undulations in the cell membrane [63] 
and its enhancement is consistent with increased movement of the cell membrane due to a 
decrease in cell adhesions. 
 
Figure 2.4. Biodynamic tissue response spectrograms of tumor spheroids responding to 
different cytoskeletal drugs. All drugs were administered at 10 μg/mL concentrations. 
BDI of HT-29 and PaCa-2 spheroids used a faster frame rate (25 fps) compared with BDI 
of UMR-106 (10 fps). The response of HT-29 to the microtubule-affecting drugs—
paclitaxel (Taxol), nocodazole (Noco.), and colchicine (Colch.)—was noticeably 
different from the response of PACA-2 or UMR-106. The white lines highlight the zero-
contour of the relevant feature.  
The intensity and duration of the mid-frequency enhancement (Figure 2.5) caused 
by cytochalasin-D were proportional to the relative cell adhesion strengths of the three 




frequency about which the enhancement is centered which decreases with increasing 
relative cell adhesion strength, indicative of the resistive influence that cell adhesions 
have on the motion of the cell membrane. 
 
 
Figure 2.5. Response to cytochalasin-D. Center frequency, amplitude, and duration of 
mid-frequency enhancement measured from tissue dynamic response spectrograms for 
cytochalasin-D applied to different cell lines. As the relative adhesion strength of the cell 
line increases, the enhancement shifts to lower frequencies, suggesting slower motion, 
and has higher amplitude and longer duration. 
 
 
The response to colchicine, nocodazole, and paclitaxel (Figure 2.4) in UMR-106 
and PaCa-2 showed a low-frequency enhancement that shifts to lower frequencies with 
increasing relative adhesion strength. Significantly, HT-29 response to these microtubule 




above 1 Hz. This high-frequency enhancement was observed in the UMR-106 and in 
PaCa-2 at or above 5 Hz. 
 
2.5 Influence of Growth on Cell Adhesion Formation 
To test the effect of different growth techniques on drug responsivity, tissue 
response was measured for three different cell culture growth environments: tumor 
spheroids, cell pellets, and cells suspended in agar [78]. 
The response in UMR-106 to colchicine and paclitaxel (Figure 2.6) is consistent 
between tumor spheroids and cells in suspension.  Colchicine shows a characteristic low-
frequency (0-0.1 Hz) enhancement that reflects changes in cell shape due to reduction in 
cytoskeletal stiffness by inhibition of microtubule polymerization. The features of the 
response spectrogram shift from 0.05 Hz in the cell suspension to 0.1 Hz in the tumor 






Figure 2.6. Comparison of tissue response spectrograms for UMR-106 to cytoskeletal 
drugs.  Response spectrograms for cells in suspension (Susp.) under colchicine (Colch.) 
and paclitaxel (Taxol) present features (marked by the white lines) consistent with those 
for the tumor spheroids (Spher.) under the same drug. However, the response 
spectrogram for cells in suspension under cytochalasin-D (Cyto.) lacks the mid-range 
(0.1-1 Hz) enhancement seen in the tumor spheroid (white square). The white lines and 
square highlight the zero-contour of the relevant feature. 
 
On the other hand, the response to cytochalasin-D in UMR-106 (Figure 2.6) is 
inconsistent between tumor spheroids and cells in suspension, and the mid-range (0.1-1 
Hz) spheroid enhancement response is not present in the response of the cells in 
suspension. This lack of mid-range enhancement was found to be independent of the dose 
of cytochalasin-D, although the cells in suspension exhibit a overall suppression 






Figure 2.7. Dose dependent response to cytochalasin-D for UMR-106 cells in suspension. 
Tissue response spectrograms for UMR-106 cells in suspension under cytochalasin-D at 
concentrations of 0, 0.01, 0.1, 1 and 10 μg/mL lack mid-range (0.1-1 Hz) enhancement at 
all doses. However, the average of the differential response shows an overall suppression 
whose saturation time decreases monotonically with increasing concentration. The 
saturation time estimates how quickly the cytochalasin-D affects the cells in suspension. 
Average differential response is averaged over frequencies from 0.005 to 1 Hz. The 
samples under 0 and 0.1 μg/mL cytochalasin-D have an slight initial enhancement 
relative to the baseline (0.095 and 0.126, respectively) that offsets the overall suppression 
measured. 
 
Tumor spheroids and cell suspensions of PaCa-2 (Figure 2.8) show a difference in 
their respective drug responses that is similar to the difference in drug response of UMR-
106, with the cell suspensions lacking an enhancement feature in the mid-frequencies that 
occurs in the drug response of the tumor spheroids. Spectrogram features for PaCa-2 




which is consistent with the hypothesis that the lower adhesion density of PaCa-2 allows 
for faster cell membrane motion when the cytoskeletal drugs are applied.  
To investigate the transition in response between the adhesion-poor environment 
of the cells in suspension and the adhesion-rich environment of the tumor spheroids, we 
measured the response of dense cell pellets formed from cell cultures. These pellets are 
optically dense like tumor spheroids, but initially they have fewer adhesions. Incubating 
the pellets allows adhesions to form. Cell pellets of PaCa-2 were treated with 
cytochalasin-D and their response was measured to rule out sample density and scattering 
frequency as the cause of this difference in drug response. Differing levels of cell 
adhesions were allowed to develop by changing the time over which the pellets were 
incubated. Pellets that received no incubation prior to testing showed a drug-response 
similar to that of the cell suspensions. After 24 hours of incubation, cell pellet drug-
response showed a moderate enhancement in the mid-frequencies, becoming more like 
the tumor spheroid response, indicating increased formation of cell contacts prior to drug 






Figure 2.8. Tissue response spectrograms of PaCa-2 to cytochalasin-D and colchicine for 
cells in suspension (Susp.), cell pellets, and tumor spheroids (Spher.). Cell pellets were 
tested after 0 and 24 hours of incubation. The response to colchicine consistently shows a 
strong low-frequency range enhancement. The response of the cell pellets to 
cytochalasin-D demonstrated a transition in responses with the response of samples 
without incubation (0 hr) being similar to the response of cell suspensions, lacking the 
enhancement associated with changes in the cellular adhesions. After 24 hours of 
incubation the response becomes closer to that of the tumor spheroid and begins to show 
the expected enhancement (indicated by the white oval). 
 
2.6 Discussion and Conclusion 
Predicting cancer response to chemotherapies requires culture models that 
accurately mimic the native tissue microenvironment and requires assays that can 
measure cell response within that environment.  In the present study, we used digital 
holography in the form of biodynamic imaging to study the response of multicellular 
tumor spheroids, a common 3D tissue model, to several cytoskeletal drugs. We also 
investigated how this response is altered by differences in the level of cellular adhesions 




Tumor spheroids of the three cell lines—HT-29, UMR-106, and PaCa-2—
displayed strong changes in cellular motion in response to disruption of the cytoskeleton. 
For the UMR-106 and PaCa-2 cell lines, changes to the microtubules resulted in similar 
alterations in the cellular motion irrespective of whether the disruption was due to 
polymerization or depolymerization. The changes due to microtubule disruption for HT-
29, however, are significantly different from those of UMR-106 and PaCa-2 over the 
frequencies measured. Cohen [81] showed that microtubule disruption in HT-29 induced 
cell differentiation and was accompanied by assembly and reorganization of the actin 
microfilaments, which suggests that HT-29 displays a response to nocodazole, colchicine, 
and paclitaxel that is physiologically different from that of UMR-106 or PaCa-2. 
Tumor spheroids and cells in suspension exhibit significantly different behavior in 
response to cytochalasin-D for the UMR-106 and PaCa-2 cell lines. Drug dosage does not 
account for this difference, with dose only influencing how quickly a drug affects the 
cells. While cytochalasin-D appears to induce cell death in both the tumor spheroids and 
cells in suspension, only the adhesion-rich tumor spheroids showed significant increase in 
membrane motion accompanying the actin microfilament depolymerization. Ujihara 
found that actin disruption by cytochalasin-D significantly decreased adhesion area in 
fibroblasts while microtubule disruption by colchicine had a much smaller effect [82]. 
Greater decrease in adhesion area would account for the stronger difference in tissue 
response due to cytochalasin-D relative to colchicine observed between adhesion-rich and 
adhesion-poor culture models. 
Holographic biodynamic imaging measurements on cell pellets with variable 




This suggests that the difference in response shown by the cell suspensions and tumor 
spheroids is not due to differences in sample density, but is caused by changes in the 
microenvironment during incubation and is a strong indication of the influence of cell-
cell contacts and the extracellular matrix on overall sample response to chemotherapeutic 
drugs. 
In conclusion, a systematic study was performed of dynamic light scattering 
signals as a function of the adhesion strength among the cells in tissues grown from 
different cell lines and different growth environments.  A clear signature of membrane 
fluctuations was observed in mid frequencies (0.1 – 1 Hz) that was enhanced by the 
application of cytochalasin-D that degrades the actin cortex inside the cell membrane.  
This enhancement feature is only observed in tissues that have formed adhesions, because 
cell pellets initially do not show this signature, but develop this signature after incubation 
enables adhesions to form.  Digital holography, and in particular biodynamic imaging 
that uses digital holography to capture tissue dynamics, provides a new analysis 






CHAPTER 3. OVARIAN CANCER CELL LINES SENSITIVITY TO PLATINUM 
THERAPY 
3.1 Abstract 
Three-dimensional (3D) tissue cultures are replacing conventional two-
dimensional (2D) cultures for applications in cancer drug development.  However, direct 
comparisons of in vitro 3D models relative to in vivo models derived from the same cell 
lines have not been reported because of the lack of sensitive optical probes that can 
extract high-content information from deep inside living tissue.  This chapter discusses 
the use of BDI to measure response to platinum in 3D living tissue.  Human ovarian 
cancer cell lines were grown either in vitro as 3D multicellular monoculture spheroids or 
as xenografts in nude mice. Fragments of xenografts grown in vivo in nude mice from a 
platinum-sensitive human ovarian cell line showed rapid and dramatic signatures of 
induced cell death when exposed to platinum ex vivo, while the corresponding 3D 
multicellular spheroids grown in vitro showed negligible response.  The differences in 
drug response between in vivo and in vitro growth have important implications for 
predicting chemotherapeutic response using tumor biopsies from patients or patient-
derived xenografts.  This chapter also discusses the use of BDI for ex vivo testing of in 




in vivo showed decreased sensitivity to ex vivo re-exposure when compared to xenografts 
from untreated mice.  This is the first time BDI has been used to assess the efficacy of in 
vivo treatment [3]. 
 
3.2 Introduction 
Ovarian cancer accounts for 3% of all cancers in women. It is the fifth deadliest 
overall and the most deadly gynecological variant, killing 14,030 women in the United 
States in 2013. That same year 22,240 new cases were diagnosed [83, 84]. 
Approximately 80% of patients diagnosed with epithelial ovarian cancer (EOC) will 
relapse after first-line platinum-based and taxane-based chemotherapy. The average 
duration of survival after EOC recurrence is 12 to 18 months.  Currently, fewer than one 
in ten patients with advanced EOC survive beyond 5 years.  On the other hand, it has 
been shown that patients whose time-to-recurrence is increased have higher rates of 
overall [85, 86].  Recurrence of ovarian cancer is associated invariably with the 
emergence of partial or complete platinum or taxane resistance. Development of a 
methodology that can predict subsequent response to treatment would be useful for 
selecting chemotherapeutic or biological agents most likely to arrest tumor growth.  At 
the present time, treatment selection is empirical, and is not individualized to tumor 
characteristics.  
Even though cells thrive in three-dimensional environments and communicate 
with near and distant neighbors, most assays in cell biology use two-dimensional cultures. 
For instance, current methodologies used to predict response to therapy include 2D 




assays have limited ability to yield cells from clinical specimens, lack predictive power 
for subsequent clinical applications [89-92], and rely solely on the epithelial tumor 
components.  It is now known that cells in 2D do not behave as cells in 3D tissues, 
displaying different genetic expression profiles [93-95], different intercellular signaling 
[96-99], and different forces attaching them to their environment [69, 100, 101].  The 
cellular dimensionality and microenvironment exert an essential influence on drug 
sensitivity [102, 103] or resistance [104, 105] of 3D cultures relative to 2D monolayers.  
Therefore, an evolution is in progress in cell-based assays transitioning from 2D cell 
culture to 3D tissue because three-dimensional tissue presents a more natural 
environment to cells [106, 107], enabling contacts to the extracellular matrix and to other 
cells that translate to intracellular signaling [95, 99] and gene expression [93, 94, 108] 
that more closely replicate the tumor environment. 
Three-dimensional tissue models that are ideal in vitro models to study complex 
three-dimensional tumor heterogeneity include multicellular tumor spheroids [15-17, 
109], tumor xenografts from mouse models that are excised and tested in vitro, and 
finally human tumor biopsies.  In spite of the distinct advantages of these 3D tissues 
[110], conventional imaging techniques are unable to penetrate deep enough within tissue 
to image the heterogeneous regions of tumors.  Here we use biodynamic imaging (BDI) 
and the signatures of different dynamical cellular functions [111, 112] to solve this 
problem. We have validated BDI in applications of drug screening and phenotypic 






3.2.1 Biology of ovarian cancer 
Ovarian cancers exhibit clinically relevant heterogeneity that makes it difficult to 
develop widely applicable treatments [84, 119]. Though surface epithelial cancer is the 
most common of ovarian cancers, there is controversy over the actual originating cells of 
different ovarian cancers [84, 119-122]. Surface epithelial ovarian cancer is classified as 
serous, endometrioid, mucinous, and clear cell type based on morphology, differentiation, 
progression, response to therapy, and prognosis. Classification is hampered by the fact 
that epithelial ovarian cancer can mimic cancers of the oviduct, uterus, and cervical canal. 
[120].  Several hypotheses have been advanced as to the cause of carcinogenesis [123-
126]. 
Primary and recurrent ovarian cancers are generally bulky, and it is accepted that 
tumor heterogeneity related to polyclonal cell expansion is omni-present and partly 
responsible for variable and incomplete responses to therapy [127] and tumor recurrence.  
The recently-released results of the human tumor genome atlas for ovarian cancer 
demonstrated that ovarian tumors are characterized by genomic chaos and that no driver 
mutations or pathway activation characterize specific ovarian tumor subsets [128].  Thus 
therapeutic progress has been hindered by the inevitable emergence of chemotherapy 
resistance and tumor heterogeneity leading to incomplete or mixed tumor response [129]. 
A2780 is an established human ovarian epithelial cancer cell line cultured from 
tumor tissue of an untreated patient. A2780 responds to platinum treatments and has been 
used as a parent cell line to derive other platinum-resistant cell lines by culturing A2780 
cells in the presence of platinum compounds. A2780/CP70 (CP70) is created by 




diamminedichloroplatinum(II) (cisplatin) up to 70 uM [130]. This cell line was later 
modified to stably express green fluorescent protein to create the A2780/CP70-GFP cell 
line (CP70-GFP). A2780cis is a platinum-resistant cell line derived from A2780 through 
chronic exposure to increasing concentrations of cisplatin [131]. 
 
3.2.2 Biochemical and biophysical effects of platinum therapies 
There is a high degree of variability in response to existing and developing EOC 
therapies.  Primary treatment is based on platinum and taxanes that follow initial surgery 
[132].  While platinum compounds have proved effective in increasing the survival rate 
among ovarian cancer patients, patient cancers frequently develop platinum-resistance. In 
many cases, these tumors also exhibit resistance to other standard-of-care therapies [130]. 
Predicting how a patient’s cancer will respond to chemotherapeutic compounds is a 
critical tool for improving patient longevity and quality of life. 
 Cisplatin, cis-diamminedichloroplatinum(II), and carboplatin, cis-Diammine(1,1-
cyclobutanedicarboxylato)platinum(II), are two common platinum compounds used to 
treat a number of cancers including ovarian, cervical, lung, and testicular types [130, 133-
135]. The primary cytotoxic action of cisplatin is DNA damage [136, 137].  Cisplatin 
resembles alkylating agents and cross-links DNA strands by bonding to certain 
nucleotides [138].  These cross-links interfere with DNA replication and transcription.  
These DNA lesions are sensed by the cell and induce DNA repair or cell death.  
Increased DNA repair in associated with ciplatin resistance.  This chapter presents a 
study of cisplatin response in sensitive (A2780) and resistant (A2780/CP70 and A2780cis) 




3.3 Materials and Methods 
3.3.1 Animal and Tissue Models 
A2780 and A2780cis ovarian cancer cells were from Sigma.  A2780/CP70 cells 
were a gift from Dr. Bob Sanders, University of Texas at Austin.  A2780/CP70-GFP cells 
were produced in Dr. Daniela Matei’s laboratory.  Cells were cultured at 37 °C in a 
humidified CO2 incubator in RPMI 1640 (Cellgro, Manassas, VA) supplemented with 10% 
fetal bovine serum (Cellgro) and 1% antibiotics [139].  
Xenografts were generated by Dr Matei’s laboratory through intraperitoneal (ip) 
implantation of 5x106 cells into 6-7 week-old nude female BalbC mice.  IP xenografts 
formed and were harvested after 4 weeks.  Harvested tumors were placed in ice cold 
media and were transported to Dr. John Turek’s laboratory within 2 hours and prepared 
for imaging. This extraction/transport/preparation protocol ensured that the samples 
experienced limited degradation during transport and preparation for BDI. 
 
3.3.2 Chemotherapy drugs 
Cisplatin and carboplatin were obtained from Selleck Chemicals. Dimethyl 
sulfoxide (DMSO) came from Sigma-Aldrich. Each drug was prepared to twice the 
desired concentration to allow for later mixing inside the sample well. DMSO dissolved 
(0.05%) in growth medium was used as the negative control in all experiments. DMSO 
was selected since cisplatin, carboplatin, and the positive control drug were each 
dissolved in DMSO before being added to growth medium to improve solubility.  
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) was used as a 




of DMSO and divided into 40 aliquots of 5 μL each. 5 mL growth medium was added to 
one aliquot of FCCP to make the 200 µM FCCP solution used in each experiment. FCCP 
was chosen as a positive control because of the strong, predictable response demonstrated 
by other cancer cell lines.  Table 3.1 shows chemical information for the three drugs. 
 
Table 3.1. Chemical information. Information obtained from manufacturer’s website. 
 
 
3.3.3 Tumor spheroids 
Spheroids were formed using two methods: rotating bioreactors (Synthecon, 
Houston, TX) as described in CHAPTER 2.3.3, and 96-well Corning U-bottom spheroid 
plates. The U-bottom growth technique generates spheroids more rapidly by using high 
cell seeding density. Plates were seeded with 1-5 x104 cells and incubated with typical 
incubation times of 48-72 hours. CP70-GFP spheroids grew slightly slower than A2780, 
though this was most likely due to low seeding density. CP70-GFP spheroids showed 




bottom samples had lower cohesion and lacked extensive cellular adhesions and had only 
minor extracellular matrix compared to the samples grown in bioreactors. 
Both 8-well slides (see CHAPTER 2.3.3) and 96-well plates were used for these 
experiments. The 96-well plates were prepared by first transplanting tumors from the 
Corning plates into standard 96-well plates (Falcon). The residual medium after pipetting 
was 50 µL. Then 75-100 µL of low gelling temperature agarose made up in medium 
without serum was added. After a gentle mixing step some of the mixture was withdrawn 
to leave approximately 100 µL of material. The spheroid was typically covered by the 
agarose. If bubbles remained in the mixture, the plate was degased at 5-7 mm Hg briefly. 
The plate was then briefly placed inside a refrigerator to allow the agar to partially 
solidify. Finally, more growth medium was added to each well and the plate was placed 
at 37 °C in a humidified CO2 incubator for 0-3 hours. 
Slides/plates were glued to a 2-axis translation stage in the OCI system to prevent 
the sample moving during observation. 8-16 tumors were selected from each slide/plate 
for testing, typically one tumor from each well. Growth medium was heated to 37 °C and 
pipetted into each well until the well was full and any bubbles were removed. 
 
3.3.4 Murine biopsies 
Tumor biopsies were harvested from the peritoneal cavity of nude mice by Dr. 
Matei’s lab (Figure 3.1). Biopsies were maintained at 4 °C for 5-48 hours before testing. 




1 mm3 in volume.  Pieces were affixed inside either 8-well or 96-well plates using a small 
drop of GLUture (Abbot Laboratories) and covered with agarose. Growth medium was 
added to each well. Experiments were performed immediately after plates were prepared. 
 
 
Figure 3.1. Photo of sacrificed mouse. Cancer cells (2x106 cells/mL) were injected into 
the peritoneal cavity of each mouse. Tumors (as one held by the forceps) formed on 
peritoneal lining and on the surface of surrounding organs.  Tumors developed (with or 
without drug) for 3 weeks prior to harvesting. 
 
3.3.5 OCI sequence 
A diagram and explanation of the OCI system is found in CHAPTER 1.5.  OCI 
frames of each tumor were captured in cycles every 20-24 minutes, for an 8-sample 
experiment, or 40-48 minutes, for a 16-sample experiment, on average. Each capture 
sequence consisted of 15-45 seconds travel time to allow the system to transition between 
tumors, followed by frame capture: 10 background frames captured at 10 frames per 
second (fps) with the reference beam not zero-path matched, then 50 frames at 0.5 fps 




Tumor spheroids were observed for 5 cycles (4 hours), for a 16-sample 
experiment, or 9 cycles (3.6 hours), for an 8-sample experiment, to allow the tumors to 
stabilize. Then half of the growth medium (~150 µL) was removed from each well and 
replaced with a drug at twice the intended concentration to minimally disturb the sample. 
Tumors were then observed for 12 or 24 cycles (9.6 hours), respectively. 
 
3.3.6 Proliferation assay 
Exponentially growing A2780 and CP70 cells were seeded in 96-well plates. 
Twenty four hours after seeding, cells were treated with 2, 4, 8, 16, 32 μM of cisplatin. 
After 72 hours of drug exposure, a cell counting kit-8 (CCK-8) assay was performed 
according to manufacturer’s specifications (Dojindi).  In a CCK-8 assay, a solution 
containing a water-soluble tetrazolium salt (WST-8) is added to the cell culture.  WST-8 
is reduced by dehydrogenases in cells to give an orange colored product (formazan), 
which is soluble in the tissue culture medium. The amount of the formazan dye generated 
by dehydrogenases in cells is directly proportional to the number of living cells.  Growth 
inhibition curves were generated, where each point represents mean ± SD of 3 replicates. 
The 50% inhibitory concentration (IC50) value was calculated by using nonlinear 
regression by fitting the normalized data to a sigmoid dose–response curve. The 
treatment of cells cultured as spheroids was carried out using the same cisplatin 





3.3.7 Logistic Predictor 
To define the performance of the predictive assay for therapy response, a logistic 
model was constructed which incorporated three biomarkers.  These are apoptosis-related 
(APOP), all-frequency (ALLF) and knee-frequency (KNEE) motility metrics (See 
Chapter 1).  These three metrics correlated most strongly with the two cell line 
populations (sensitive and insensitive).  The logistic function used is  
  3.1 
The argument ARG in the logistic function is constructed from the mean values and 
standard deviations of the motility metrics to construct a multivariable logistic predictor 
Ln of drug response for the nth sample as 
  3.2 
where m varies over the selected biomarkers, M is the number of biomarkers, bnm is the 
value of the mth biomarker for the nth sample, sm is the standard deviation of the mth 
biomarker, and Km is the Kolmogorov-Smirnov threshold between the two populations 
(responsive and non-responsive) for the mth biomarker.
 
3.4 Results 
3.4.1 Biodynamic characterization of A2780 and CP70-GFP cell lines 
The growth of tumor spheroids in the rotating bioreactor provides sufficient time 
for the tumors to generate tighter tissues, with multiple adhesions and minor extracellular 




grown in vivo.  The average NSD of the tumor spheroids are 0.82 ± 0.01 (N = 56) for 
A2780 and 0.91 ± 0.06 (N = 53) for CP70.  In addition, several samples were grown as 
co-cultures of both cell lines, and these had an average NSD of 0.85 ± 0.06 (N = 4), 
which is approximately the average of the two separate cell lines (Figure 2a).  A 
comparison of the three growth techniques (bioreactor, U-bottom and biopsy) shows that 
the U-bottom plate samples had the highest motility with an average NSD of 0.89 ± 0.03 
(N = 8) and 0.92 ± 0.01 (N = 30) for A2780 and CP70, respectively.  In general, both cell 
lines had lower motility when grown in the bioreactor (0.82 ± 0.01, N = 43; 0.89 ± 0.01, 
N = 18).  The lower bioreactor motility is consistent with the presence of more 
intercellular adhesions that constrain the motion of the cell membrane, which is a major 
contributor to the overall motility metric.  Average values for A2780 biopsies are 0.74 ± 
0.02 and for the A2780-cis biopsies are 0.78 ± 0.01 (Figure 2b). 
 
 
Figure 3.2. Average initial NSD of ovarian cultures.  The number of samples averaged is 
indicated.  Error bars show sample variability on the mean for each culture type.  Cell 
line average NSD (left) includes samples of many different growth methods, including 
tumor spheroids, cell pellets, and murine biopsies. Though the average value of the initial 
NSD depends on culture growth type (right), the sensitive cell line always shows lower 




MCI images of platinum-sensitive A2780 and platinum-insensitive CP70-GFP 
tumor spheroids (Figure 3.3) and murine biopsies show strong differences in the overall 
motility of the two cell lines. A2780 spheroids have regions of low motility tending 
toward the center of the tumor consistent with hypoxia occurring in the tumor’s central 
region. CP70-GFP spheroids are more resistant to hypoxic effects due to constitutively 
expressed HIF1-α protein [140] and show less reduction in the motility of the central 
tumor region. Co-cultured spheroids of A2780 and CP70-GFP cells tend to form regions 
where one cell line predominates. MCI images of co-cultured spheroids show 
heterogeneous portions of high- and low-motility corresponding to groupings of CP70-










Figure 3.3. Sample MCI frames for sensitive (A2780), insensitive (CP70-GFP), and co-
culture tumor spheroids. The difference in average motility is visible with A2780 tumor 
spheroids demonstrating much lower motility overall than the CP70-GFP.  The co-
cultured spheroids showed marginal heterogeneity with moderately high- and low-
motility regions. 
 
Examples of positive and negative control spectrograms are shown in Figure 3.4 
for the mitochondrial toxin FCCP (100 M) and for the carrier DMSO (0.05%). The 
compound FCCP is a mitochondrial uncoupler (inhibits the mitochondrial membrane 
polarization), and the response of both A2780 and CP70 to FCCP is characteristic of TDS 
spectrograms on tumor spheroids from other cell lines [1].  The negative controls are 
relatively nonresponsive, with minor changes over time that are typical of healthy tissue 






Figure 3.4. Tissue dynamics spectroscopy (TDS) control experiments on tumor spheroids 
from A2780 and A2780/CP70 (CP70) cell lines.  a) Positive control consisted of 100 μM 
FCCP.  b) Negative controls consisted of 0.05% DMSO. 
 
3.4.2 Prospects for Therapy Efficacy Testing 
Biodynamic imaging was used to measure the response of tumor spheroids and 
murine biopsies of platinum-sensitive and -insensitive ovarian cancer cell lines. The goal 
was to develop metrics for predicting sample response to chemotherapeutic treatments. 
Doses of 10 µM carboplatin or 10 µM cisplatin were administered to tumor spheroids 
(A2780 and CP70-GFP) and murine biopsies (A2780, CP70, and A2780cis) and tissue 
responses were measured. (However, the CP70 murine culture became infected before all 
experiments were completed, leading to low replicate numbers in some experiments). 




Table 3.2 Sample numbers for each drug group in therapy efficacy assessments. 
 
 
Results show a strong response in the A2780 murine biopsies to both carboplatin 
and cisplatin while CP70 biopsies showed no significant response to cisplatin (Figure 
3.5a). A2780cis biopsies also showed no response when treated.  Tumor spheroids of 
both A2780 and CP70-GFP cell lines showed little significant response to either 
carboplatin or cisplatin even at high doses (Figure 3.5b). This result was unexpected. 
Average baseline and dosed spectra from tumor spheroids of sensitive and resistant cell 
lines are shown in Figure 3.5c.  The baseline spectra show a normal spectral shape with 
knee frequencies at 0.018 Hz (A2780) and 0.025 Hz (CP70-GFP) and a slope of -1.2 for 
both cell lines. After treatment, the spectra show minimal changes in shape.  The average 
baseline spectra of ex vivo xenograft biopsies (Figure 3.5c) have a knee frequency and 
slope of 0.0007 Hz and -1.3 for A2780, and 0.04 Hz and -1.8 for A2780cis.  Figure 3.6 





Figure 3.5. Tissue dynamics spectroscopy results of ovarian cancer cultures exposed to 
platinum compounds. a) Average TDS response spectrograms of sensitive/insensitive cell 
lines for biopsies and spheroids responding to cisplatin and carboplatin. The biopsies 
were xenografts grown from the same cell lines as the spheroids.  The resistant biopsy 




difference in sensitivity between the A2780 explants relative to the spheroids. b) Average 
tissue dynamics response spectrograms of spheroids grown in vitro for A2780 (sensitive) 
and A2780/CP70 (resistant) cell lines and both platinum compounds for 10 μm and 50 
μM over 9 hours after dose. Average baseline and dosed power spectra for c) in vitro 
spheroids and d) ex vivo xenograft biopsies of sensitive and resistant cells lines. Knee 
frequencies and slope parameters of each spectrum are indicated.  
 
 
Figure 3.6. Inhibition, as measured by ALLF linear filter, of ovarian tumor activity in 
response to platinum therapy. 
 
Distinct dose-dependent decreases in cell viability upon treatment with cisplatin 
were observed for A2780 (sensitive) and CP70 (resistant) cells, when grown as 2D 
monolayers.  Spheroids were significantly more resistant to cisplatin compared to 2D 
cultures and differences between sensitive and resistant cells were not observed (Figure 
3.7). Vascularization of the biopsies or effects caused by the transport of samples may 
account for the difference in sample sensitivity, and experiments are continuing.  Tumor 




have mouse-derived stromal tissue as a constituent.  In addition, clonal selection may be 
different in the two different growth environments, leading to different phenotypes 
between the explants and the spheroids.  Therefore, the more natural mouse environment 
for tumor growth, and the different tissue constituents, may provide markedly different 
responses to the platinum therapy 
 
 
Figure 3.7. IC50s over 72 hours for a) 2D culture compared to b) 3D culture (tumor 
spheroids) from the same cell lines.  The sensitive cell line is A2780, and the insensitive 
cell line is A2780/CP70 (CP70).  The 3D spheroids have IC50 values approximately 10 
times larger than for 2D.  In the spheroids, both cell lines have high IC50s (72 μM and 
104 μM) over 72 hours. 
 
The sensitivity, specificity, and accuracy of the biodynamic chemoresponse assay 
on murine xenograft biopsies were measured using a logistic regression on selected 






Figure 3.8. Values for three biodynamic biomarkers (ALLF, APOP and KNEE) measured 
across 24 samples.  The samples are grouped as sensitive/carboplatin, sensitive/cisplatin, 
insensitive/cisplatin and insensitive/carboplatin.  The ALLF biomarker measures overall 
inhibition in the drug-response spectrogram.  The APOP biomarker is a nonlinear metric 
that correlates with apoptotic response.  The KNEE biomarker is the knee frequency of 
the fluctuation spectral power. 
 
By combining the three motility metrics in the multivariate logistic function, the 
combined group predicted chemotherapy response in 100% of cases using a binary 
classifier (response vs. non-response) that fully separated the two groups (Figure 3.9).  To 
test for over-fitting of the data by the logistic predictor, a one-left-out (OLO) cross 
validation analysis was performed in which the logistic function was trained using 23 of 
the biopsies, holding one of the samples back that was subsequently tested in the 
predictor.  This procedure was repeated for each of the 24 tumor fragments, and the 
results are shown in Figure 3.9 as the red bars.  The performance of the OLO assay is 




When the logistic prediction values were fit by continuous Gaussian distributions to 
generate a smooth a receiver-operator curve (ROC), the accuracy, sensitivity and 
specificity of the OLO analysis were all above 95%. 
 
 
Figure 3.9. Logistic predictor model using selected biomarkers.  The logistic predictor 
used three biomarkers (ALLF, APOP and KNEE) of 24 individual biopsy samples across 
sensitive (A2780) and resistant (A2780/CP70 and A2780cis) cell lines responding to 50 
μM cisplatin (Cisp.) and carboplatin (Carbo.) treated ex vivo.  Blue bars are results of 
training the logistic function with all samples.  Red bars are results of the one-left-out 






3.4.3 In Vivo Platinum Treatment Tested by Ex Vivo Re-exposure 
The treatment of tumors ex vivo occurs in a very different environment compared 
to the more natural chemotherapy applied in vivo for which the drug is delivered to the 
tumor through the circulatory system of the mouse.  To test the ability of biodynamic 
imaging to monitor tumor treatment in vivo, mice were treated with 50 mg/kg of 
carboplatin for varying periods of time before the mouse was sacrificed. The duration of 
the delay before sacrifice varied between 0 and 4 hours. The TDS response of the 
harvested tumor biopsies (with varying exposure time in vivo) was measured by further 
carboplatin (10 µM) treatment in vitro. 
Response spectrograms of sensitive A2780 (Figure 3.10a) biopsies show expected 
sensitivity to carboplatin in the post-harvesting measurement, but the magnitude of the 
response decreases with increasing duration of pretreatment.  The pretreatment of the 
tumors in vivo have an immediate inhibitory effect on the tumor tissue.  Figure 3.10b 
shows the influence of pretreatment on initial sample motility. The NSD motility metric 
of biopsies from the insensitive A2780cis cell line remained essentially constant for 
different pretreatment times. However, the sensitive A2780 samples showed a decrease in 
initial NSD motility as pretreatment time increased.  This demonstrates the sensitivity of 
biodynamic imaging to the state of health of the biopsies and the ability to measure, using 







Figure 3.10. Response of A2780 xenograft biopsy to 10 µM carboplatin re-exposure ex 
vivo following carboplatin pretreatment. TDS drug response spectrograms show re-
exposure for biopsies pretreated in vivo with 50 mg/kg carboplatin for 0.5 hr, 1 hr, 3 hr 
and 4 hr treatment. Xenograft fragments were then re-exposed during BDI assessment. a) 
Re-exposure of samples to carboplatin demonstrate low-frequency suppression, the 
amplitude of which correlated with decreasing time since initial treatment. The response 
to further treatment decreased with increasing pretreatment time. b) Effect of carboplatin 
pretreatment on sample health for sensitive (A2780) and insensitive (A2780cis) cell lines. 
Relative NSD is calculated by shifting the origin of the y-axis so that the average baseline 
NSD of the untreated samples for each day’s experiment is unity. This reduces the 
systematic influences on average values and allows for comparison of experiments run on 
different days. 
 
The drug-response spectrograms of Figure 3.10 were quantified by applying 
feature masks to the time-frequency spectrograms for feature extraction and 
quantification.  Different feature masks correspond to different dynamical “biomarkers” 
or signatures of tissue response.  One of the strongest biomarkers for chemotherapy 
response is the “dipole” feature mask that measures overall shift in spectral weight. A 
shift of spectral weight to lower frequencies constitutes metabolic inhibition and is 




organelle/vesicle activity that appears near the Nyquist frequency.  Enhanced organelle 
activity has been associated with apoptotic processes [141].  The metabolic inhibition and 
organelle activity biomarkers are plotted in Figure 3.11 as a function of the duration of 
the in vivo treatment time.  These values correspond to the response of the pretreated 
tissues to an in vitro dose of platinum.  Increasing treatments decrease this second 
response.  Tumors that have been degraded by treatment in vivo before surgery are less 
healthy (reflected in the measured NSD values) and hence will not respond as strongly 
because the tissue is less viable than untreated or more weakly-treated samples. 
 
 
Figure 3.11. Spectral response to re-dosing.  Spectral response measures average spectral 
change across masked spectrograms. Masks select for specific biological processes. 
Metabolic inhibition is the total average response (ALLF) while organelle/vesicle activity 





3.5 Discussion and Conclusion 
Technologies that accurately assess the efficacy of chemotherapy could play a 
pivotal role in cancer care.  The body is essentially a black box, opaque to most types of 
imaging, while for body-penetrating techniques (such as ultrasound or MRI), it allows 
only limited spatial resolution.  Although the ultimate goal would be to observe, with 
microscopic resolution, cancer tissue responding to treatment in the patient in real time, 
imaging technology has not yet reached this stage.  Compounding the difficulties of in 
vivo imaging are difficulties of finding specific biomarkers of treatment response.  In 
many assessment techniques, tumor size reduction is the principal biomarker that 
provides a measure of the objective response to therapy.  However, even if a therapy can 
kill most of a tumor, thereby providing a positive response measure, spatial heterogeneity 
in the tumor and its environment can prevent therapy from killing all of the cancer, which 
ultimately will relapse.   
 Biodynamic imaging may provide some solutions to this problem of therapy 
efficacy assessment.  Although the BDI technology is not currently configured to image 
tissue in vivo, the next best thing is to measure fresh living tissue ex vivo.  Excised living 
tissues can be maintained in a healthy state for more than a day by providing nutrients 
and oxygen to small tissue samples.  The tissue inside the samples retain their essential 
3D environment and microenvironment constituents (extracellular matrix, stromal tissue, 
etc.) and hence retain the ability to respond naturally to applied drugs.  In this way, BDI 
approaches the ideal of measuring drug treatment efficacy in situ.  The further challenge 
of specificity for biomarkers of assessment techniques is also provided by BDI.  




The image contrast from Doppler light scattering arises entirely from changes in the 
physiology and mechanical motions induced by applied therapeutics.  The altered 
dynamics of cells and tissues provides a direct measure of the mechanistic effects of the 
drug on the tissue.  Furthermore, biodynamic imaging on small samples can measure 
spatial heterogeneity, isolating regions of tissue that have different responses, or that do 
not respond to the applied therapeutic.  This capability of BDI could be potentially 
valuable for prediction of progression free times. 
 Chemotherapy response assays on ex vivo biopsies have two different applications 
in the clinic.  These are therapy selection, and therapy monitoring.  Therapy selection 
typically takes place after patient relapse when multiple salvage therapies are being 
evaluated.  However, an application of growing utility in the clinic for chemoresponse 
assays is the selection of therapies even before first-line therapies and standard-of-care 
are selected.  By personalizing therapy to the patient from the beginning of treatment, 
precious time would be saved for patients who do not respond to standard-of-care.  The 
second application of biopsy-based chemoresponse assays for therapy monitoring is not 
typically as useful, because most patients do not undergo surgery during chemotherapy.  
However, for laboratory studies or preclincal trials, therapy monitoring of biopsies 
provides a valuable measure for drug development. 
 In this chapter, biodynamic imaging (BDI) was demonstrated for the first time in 
preclinical trials in the second application of therapy monitoring.  Biopsies of sensitive 
and resistant tumor xenografts were tested for platinum sensitivity from untreated 
animals, as well as for platinum sensitivity from animals that had undergone initial 




sensitivity/resistance of the tumor tissues to platinum.  As expected, cell lines known to 
be sensitive to platinum produced tumor xenografts that were sensitive when tested as 
biopsies ex vivo, both with and without pretreatment in the mouse.  Conversely, the cell 
line known to be resistant to platinum produced biopsy explants that were resistant to 
platinum in ex vivo treatments.  BDI assessment of response vs. non-response using a 
multivariate logistic function resulted in 100% discrimination between known sensitive 
and resistant populations.. 
 In contrast to this high-accuracy performance of the BDI chemoresponse assay on 
murine biopsies, the same assays run on tumor spheroids grown by both bioreactor and u-
bottom plate techniques showed almost no differential response to platinum between the 
two cell lines.  This null result on the in vitro-grown 3D tissue culture has important 
ramifications on several fronts.  First, it highlights a potentially important difference 
between in vitro and in vivo tissue growth.  These two environments are radically 
different and may induce the outgrowth of different clonal populations.  Furthermore, the 
in vivo growth includes stromal cells and tissues that are missing from the in vitro culture.  
These different microenvironmental cues are known to lead to different gene expression 
and altered signaling pathways, which may contribute to the difference in the 
experimental responses to platinum.  Second, the null results on the 3D tumor spheroids 
for cell lines with known sensitivity/resistance to platinum in 2D may highlight critical 
differences between 2D and 3D culture.  It is clear that drug transport in 3D culture is 
different than for 2D monolayers, leading to EC50 values that can differ by an order of 
magnitude.  The use of 3D culture for chemoresponse testing requires much higher 




These issues can confound interpretations and predictions from 3D culture assays.  On 
the other hand, the biopsy explants do show the anticipated sensitivity/resistance to 
platinum that is predicted by 2D studies on these same cell lines. 
 Ultimately, it is the chemoresponse of tumor tissue in vivo that is most relevant 
for therapy monitoring.  The differential response to platinum of the A2780 and CP70 
explants demonstrates the unique utility of biodynamic imaging for chemoresponse 
testing in the relevant tissue environment.  Furthermore, pretreatment with platinum of 
the mice in vivo prior to surgery had a clear effect on the BDI response on subsequent 
retreatment ex vivo, further demonstrating the utility of BDI for therapy monitoring 






CHAPTER 4. HETEROGENOUS RESPONSE TO PLATINUM IN METASTATIC 
OVARIAN CANCER 
4.1 Introduction 
4.1.1 Multidrug resistance (MDR) 
The development of drug resistance in cancer patients inhibits effective treatment 
and decreases patient survival.  Cisplatin and other platinum compounds have proved to 
be effective at treating epithelial ovarian cancer, but have a high probability of inducing 
drug resistance in treated patient cancers. In many cases, these tumors also exhibit 
resistance to other standard-of-care therapies [130].  The origin of platinum resistance is 
not well understood.  Research shows that tumor microenvironment plays a significant 
role [105, 142-144].  Since metastasis changes the microenvironment of tumor cells as 
they travel to new areas of the body, metastatic tumors may also exhibit significant 
changes in platinum sensitivity. 
 
4.1.2 Tissue Structure and Mechanics 
Animal tissue can be separated into four broad categories [145]. Mesenchymal 
tissue is composed of fibroblast cells that form collagen fibers that make up cartilage, 
bones, muscles, and blood vessels as well as other structural tissues.  Epithelial cells are 
specialized organ cells that make up the liver, skin, intestines, glands, etc.  Haemato-




cells, lymphocites, and macrophages.  Nervous system cells make up the brain, spinal 
column, and nerves throughout the body.  Figure 4.1 is an illustration of the how these 
cells relate.  Epithelial tissue is of particular importance in the study of cancer as over 90 
percent of all cancer originates in the epithelium [83]. 
 
 
Figure 4.1.  Illustration of tissue components.  Epithelial cells (A) are supported by 
collagen fibers (B) generated by fibroblast cells (C).  Running through the mesenchyme 
are nerve bundles (D) and blood vessels (E).  Collagen fibers in regions such as the skin 
are supported by muscle cells (F). 
 
4.1.3 Cancer 
Cancer can be broadly defined as the invasive, proliferative growth of an aberrant 
tissue.  Normal tissue cells, exposed to a carcinogenic agent, mutate.  Though mutation is 
a normal and beneficiary process of evolution, many mutations result in dysfunction 
within the cell and threaten survivability of the organism.  Thus, regulatory mechanisms 




regulatory mechanisms, the cell can grow and proliferate without bound, turning into 
cancerous tissue that invades and overcrowds the surrounding tissue and can lead to death 
of the parent organism. 
Cancer typically begins in the epithelium and follows three stages.  During 
initiation, epithelial stem cells are exposed to carcinogenic agents.  This exposure can be 
prolonged without tissue becoming cancerous.  Individual cells affect the behavior of 
surrounding cells and the components of the interstitial environment, which gives rise to 
a field effect that precedes the formation of cancerous lesions and is an area of active 
research for early cancer detection [146]. 
Once a cell has mutated sufficiently to overcome limiting mechanisms, promotion 
leads to clonal expansion of the initiated cells within the local tissue.  During this stage 
tumor lesions form within the surrounding epithelium, though such lesions may present 
little visual difference from normal epithelial cells.  Promotion passes into proliferation, 
as the aberrant cells invade surrounding regions and penetrate into the mesenchyme. 
 
4.1.4 Metastasis 
Metastasis is the formation of cancerous bodies at some distance from the parent 
cells.  Once cancerous cells progress beyond the epithelium where they originated, they 
begin to invade other organs through the mesenchyme.  This can occur through direct 
growth of cancerous tissue, or through proliferation into the lymphatic system or the 
blood vessels.  Once inside the lymphatic or blood vessels, cancer cells can detach from 




Metastatic tumors present a mixture of parent and transplant environments.  
Tumor cells have genetic heritage from the parent epithelium from which they derived, 
but structural and chemical differences in the host location can alter expression and 
behavior.  Thus, the phenotype of metastatic and primary tumors can vary.  The primary 
way ovarian cancer spreads was thought to be continuous exposure of abdominal organs 
to free-floating tumour cells. However, there is evidence that metastasis to the peritoneal 
cavity may be carried through the blood [147]. The preferential host of metastatic ovarian 
cancer is the omentum.  The omentum is a large fold of peritoneum that hangs down from 
the stomach and encloses the small intestines and other abdominal viscera.  Nieman, et al. 
showed that the adipocyte-rich omentum provides a proliferative advantage and transfers 
fatty acids to ovarian cancer cells [148].  This chapter investigates the effect metastasis 
has on ovarian tumor sensitivity to cisplatin studied through biodynamic imaging. 
 
4.2 Materials and Methods 
4.2.1 Animal and Tissue Models 
A2780 and SK-OV-3 (SKOV3) ovarian cancer cells were from Sigma. 
Xenografts were generated by Dr. Daniela Matei’s laboratory through orthotopic 
implantation of 5x106 cells into the ovary of 6-7 week-old nude female BalbC mice.  
Xenografts formed and metastasized.  Primary and metastatic tumors were harvested after 
4-6 weeks.  Harvested tumors were placed in ice cold media and were transported to Dr. 
John Turek’s laboratory within 2 hours and prepared for imaging. Sample information is 





Table 4.1. Outline of mouse experiments. Group g1 received a larger panel of drugs 
during testing than did other groups.  Group g10 samples came from a mouse that was 
dying at the time of harvest. Sample was poor making data quality suspect.  Response 
from g10 was not included in analysis. 
 
 
4.2.2 Chemotherapy drugs 
Cisplatin was obtained from Selleck Chemicals. Dimethyl sulfoxide (DMSO) 
came from Sigma-Aldrich. Cisplatin was prepared to twice the desired concentration to 
allow for later mixing inside the sample well. DMSO (0.1%) dissolved in growth medium 
was used as the negative control in all experiments. DMSO was selected because 






4.2.3 Murine biopsies 
Tumor biopsies were harvested from nude mice by Dr. Matei’s lab. Biopsies were 
maintained at 4 °C for 5-48 hours before testing. Biopsies were sectioned using a razor 
blade to cut the tumor into pieces of approximately 1 mm3 in volume.  Pieces were 
affixed inside 96-well plates using a small drop of GLUture (Abbot Laboratories) and 
covered with agarose. Growth medium was added to each well. Experiments were 
performed immediately after plates were prepared. 
 
4.2.4 OCI sequence 
A diagram and explanation of the OCI system is shown in CHAPTER 1.5.  OCI 
frames of each xenograft tumor section were captured in cycles every 40-48 minutes on 
average. Each capture sequence consisted of 15-45 seconds of travel time to allow the 
system to transition between tumors, followed by frame capture: 10 background frames 
captured at 10 frames per second (fps) with the reference beam not zero-path matched, 
then 50 frames at 0.5 fps and 500 frames at 25 fps with the reference beam zero-path 
matched. 
Tumor sections were observed for 6 cycles (4.8 hours) to allow the samples to 
stabilize. Then half of the growth medium (~150 µL) was removed from each well and 
replaced with a drug at twice the intended concentration to limit disturbing the sample. 





4.2.5 Patient-derived xenografts (PDX) 
Patient-derived xenograft tumors were supplied by Dr. Matei.  Patient-derived 
xenografts are tumors cultured from biopsied patient cancer cells and grown in nude mice.  
Their genetic heritage is that of the derived patient cancer cells.  It is unknown if and how 
the murine environment alters phenotypic response. 
 
4.3 Results 
4.3.1 Changes in platinum sensitivity of metastatic tumors 
Samples from a single mouse group were tested over a two-day period.  It was 
uncertain if biopsy samples would still be viable for testing after 24-48 hours post-
operation.  Figure 4.2 shows the distributions of initial NSD values for primary and 
metastatic samples for both A2780 and SKOV3 cell lines.  Initial NSD values had 
considerable sample-to-sample variance, but there was no significant difference between 
the distributions for primary and metastatic samples.  However, the initial condition of 






Figure 4.2. Distribution of initial a) NSD and b) backscatter brightness values of A2780 






Figure 4.3. Comparison of initial sample NSD and backscatter brightness (BB) for 
ovarian injection biopsies.  The first data point in each set corresponds to day 1 values 
and the second corresponds to day 2.  Error bars represent standard error on the mean.  
There was variance in the NSD and BB from day 1 to day 2, but no systematic trend 
between days.
 
Response to cisplatin (25 μM) and to DMSO (0.1%) for each experimental group 
is shown in Figure 4.4.  Samples exposed to the carrier (negative control) display a non-
zero response that can be characterized as sample drift.  The excision of samples from 
living hosts and subsequent transport, sample separation, and immobilization is likely to 
cause trauma to all samples.  The response to the DMSO carrier can be considered a 
natural background to drug responses.  The greater challenge is the wide variability of 
sample response among samples from the same host, that may represent spatial 
heterogeneity consisting of varying tissue constitution (stromal, epithelial, cancerous, 




group responses.  However, response spectrograms generally demonstrated an 
enhancement in the low-frequency band up to 0.1 Hz for metastatic tumors over the 
primary tumor response.   
 
 
Figure 4.4. Average sample response for each experimental group.  DMSO (0.1%) and 
cisplatin (25 μM) responses are shown for each group of samples, separated by cell line 
and sample type—primary or metastatic. 
 
This enhancement is more easily seen in the average primary and metastatic 
responses shown in Figure 4.5.  This enhancement was common for both A2780 and 







Figure 4.5. Average response to 25 μM cisplatin (DMSO subtracted).  Response for 
primary and metastatic samples is shown for both A2780 and SKOV3 cell lines.  DMSO 
response for each group has been subtracted prior to averaging.  The difference between 
primary and metastatic responses is also shown. 
 
Figure 4.6 compares the response to cisplatin of intraperitoneal (IP) and 
othotopically injected tumors.  The more recent orthotopic A2780 tumors had weaker 
response to cisplatin than had the IP tumors reported in CHAPTER 3.  The orthotopic 
SKOV3 tumors showed response to cisplatin.  This was unexpected as the literature has 
classified SKOV3 as cisplatin-resistant.  The cisplatin sensitivity may be due to genetic 
mutations in the established line since its sensitivity was first reported, or this may 






Figure 4.6. Comparison of ovarian tumor response (DMSO subtracted) to cisplatin.  
Intraperitoneal (IP) A2780 tumors exhibited a much stronger response to ciplatin than did 
the othotopically (Ortho) grown tumors.  The SKOV3, which are classified in the 
literature as a resistant cell line, showed considerable response to cisplatin treatment. 
 
Because tumor samples demonstrated a significant response to DMSO, it is 
important to account for systematic drifts in the population behavior that are not due to 
the application of cisplatin.  Figure 4.7a shows the average response of all samples to any 
perturbation, DMSO or cisplatin.  This response can be considered the average drift in 
population response as the experiment progressed through 9 hours of observation.  The 
population drift was subtracted from each group response and the resulting average 
response for primary and metastatic tumors is shown in Figure 4.7b.  Note that the 





Figure 4.7. Correcting for sample population drift.  a) Average response spectrograms of 
each population to any perturbation, DMSO or cisplatin, show drift in sample behavior 
due to natural degradation of the tissue. b) Spectrograms show average response for 
primary and metastatic tumors with the population response removed to correct for 
changes in sample behavior not due to application of cisplatin. 
 
The change in logistic predictor values for each group using the response 
corrected for population drift maintains the trend of increased resistance in A2780 
metastatic tumors (Figure 4.8).  The SKOV3 tumors, however, show no strong trends in 






Figure 4.8. Change in resistance to platinum therapy between metastatic and primary 
tumors. 
 
4.3.2 Patient-derived xenograft (PDX) response to cisplatin 
Patient-derived xenografts (PDX) are an emerging in vitro 3D tumor model for 
culturing patient cancer cells in a laboratory environment.  Preliminary to testing human 
ovarian patient biopsies, patient-derived murine-implanted tumors were assayed.  Figure 
4.9 shows the BDI response for one patient PDX. 
 
Figure 4.9. Average response spectrograms for primary and metastatic PDX tumors 
derived from single human patient.  Metastatic samples showed stronger suppression in 




The metastatic PDX for this patient showed greater suppression in the mid to low 
frequencies indicative of increased sensitivity to cisplatin verses the primary PDX 
samples.  The primary sample still showed some sensitivity to cisplatin.  Results 
correlated well with conventional sensitivity assay results supplied by Dr. Matei. 
 
4.4 Discussion and Conclusion 
Orthotopic tumor biopsies present distinct challenges over the in vitro tissue 
models our group has used in the past.  These tumors present a more organic structure 
that includes many different cell types that are difficult to differentiate using current 
technologies.  This led to a higher variance in sample response than was previously 
observed in other 3D tissue models.  Current research is developing new methods to 
address response measurements of strongly heterogeneous tissue (see CHAPTER 5). 
A2780 tumors exhibit greater change in sensitivity to cisplatin compared with 
SKOV3 tumors for metastatics versus primaries.  Primary A2780 tumors in mouse 
groups 2, 4, 5, 6 and 7 showed sensitivity to cisplatin that decreased in the corresponding 
metastatic tumor samples. This decrease was present even when the metastatic tumors 
exhibited a sensitive response. Decrease in sensitivity suggests that metastatic cells may 
have developed better mechanisms for resisting and repairing cisplatin damage.  
Curiously, sample group 8 showed little response in the primary tumors.  The metastatic 
tumors of that same group had a sensitive response.  It is unclear why this particular 
mouse group would present an opposite trend.  However, when corrected for baseline 




The SKOV3 tumors, in general, showed sensitivity to cisplatin.  This differs from 
publish cisplatin sensitivity assessed using 2D assays [149].  The change in sensitivity 
between primary and metastatic SKOV3 tumors in smaller than that of the A2780 tumors, 
suggesting that metastatic SKOV3 cells retain greater phenotypic similarity to the parent 
tumor cells.  Both SKOV3 and A2780 metastatic tumors showed enhancement in their 
response below 0.1 Hz, indicating a common mechanism of cisplatin resistance. 
The PDX sample had an effect opposite that shown by the established cell lines, 
with metastasis displaying increased sensitivity to cisplatin therapy.  This result raises 
questions about the validity of established cell lines as accurate models for drug therapy 
development.  Patient cancers may be more chaotic than current development protocols 
assume, which would be a major factor in drug failure during clinical trials.  The 
unexpected sensitivity of SKOV3 tumors suggests that clonal variations may have 
entered into the established cell line that would alter their behavior from that of the 







CHAPTER 5. TISSUE DYNAMICS SPECTROSCOPIC IMAGING (TDSI) 
5.1 Abstract 
Spectrograms generated by tissue dynamic spectroscopy (TDS) indicate average 
cell behavior across the entire sample tissue.  When tissue is strongly homogenous, the 
average cell behavior closely matches individual cell behavior.  However, when tissue 
has heterogeneous structure, TDS spectrograms combine the different cellular responses, 
producing an average that may differ from the local tissue responses in certain regions of 
the sample.  In patient biopsy tissue—where samples contain varying amounts of 
cancerous cells, normal organ cells, and structural tissues—regional differences in tissue 
response can be large. A method for assessing the heterogeneity of response within a 
sample is needed.  This chapter discusses the development of tissue dynamics 
spectroscopic imaging (TDSI), an imaging modality that applies TDS on a voxel-by-
voxel basis across the sample to map differences in regional tissue response.  It also 
presents early work looking at regional differences in tissue response that might confound 
or invalidate predictions of patient outcome from tested biopsies. 
 
5.2 Introduction 
Correct identification of tissue response is critical if BDI is to achieve clinical 




BDI, increasing error and misdiagnosis.  As shown in Figure 5.1, ex vivo tissue, whether 
it is murine xenografts or patient biopsies, is comprised of several different cell types.  
Cancerous cells, normal organ cells, structural components, and blood vessels are all 
bound together.  Without employing other imaging techniques, it is often difficult for 
OCI, MCI, or TDS modalities to determine cell type.  However, each cell type may 
contribute differently to the measured sample response, confounding assessments.  Even 
different cancerous cells may respond differently with parts of the tumor exhibiting a 
sensitive phenotype while other parts are resistant to applied therapeutics.  BDI must 




Figure 5.1. Histology images of stained biopsy tissue samples.  Histology shows that 
biopsy samples are comprised of several different cell types and structures including: (A) 
cancer cells, (B) blood vessels, (C) stromal tissue, (D) normal organ cells, and (E) mucin.  







To this end, tissue dynamics spectroscopic imaging (TDSI) is an extension of 
TDS that uses different biodynamic response features as the imaging contrast.  It is a 
form of functional imaging [34, 47, 150] that helps detect regional differences in 
response behavior within a sample. 
 
5.2.1 Early TDSI 
TDSI has been developing since the start of biodynamic imaging.  In early tumor 
spheroid experiments, Jeong, et al. [14] noted that MCI images of large UMR-106 
spheroids showed a low-motility region in the center (Figure 5.2).  This corresponded to 
cells in the center of the spheroid being starved for nutrients, which caused them to 
undergo necrosis.  Jeong found that sectioning the OCI images into “shell” and “core” 
regions during BDI analysis resulted in spectrograms that often showed differences in 
tissue response between the two regions.  There was, however, no standardized method 
for determining which parts of the image were shell regions and which parts were core 
region, so sectioning was chosen by the operator.  Furthermore, BDI analysis algorithms 
only accepted circular or elliptical masks for sectioning.  While working with cell lines 
that formed tight spheres, such as UMR-106 or HT-29, circular masks were sufficient, 
but once projects involved biopsied tissue or cell lines that didn’t form spheres in the 
bioreactor, such as MIA-PaCa-2, more complicated sectioning geometries were needed.  
As biopsies and MIA-PaCa-2 tumor spheroids lacked the nutrient-starved central region, 






Figure 5.2. Differences in shell-core response measured by BDI.  MCI images (a) of large 
UMR-106 tumor spheroids often exhibited central, low-motility regions.  These central 
“core” regions showed different response to treatment (b) from the outer “shell” region of 
the spheroid as well as different changes in motility (c). 
Several attempts at functional imaging of heterogeneous tissue have occurred 
since those early experiments.  A2780 and A2780/CP70-GFP (CP70-GFP) cell lines 
showed distinctly different average motilities.  When co-cultured in the same bioreactor, 
tumor spheroids would form as aggregates of the two cell lines with each cell type 
preferentially clustering with itself.  This lead to spheroids with distinct regions 
comprised of A2780 and CP70-GFP cells.  MCI images of co-cultured spheroids showed 
regions of high and low motility that corresponded to CP70-GFP and A2780 cell regions, 
respectively, as confirmed by fluorescence imaging (Figure 5.3).  However, the high 
resistance of A2780 and CP70-GFP tumor spheroids to platinum compounds (see 







Figure 5.3. MCI and fluorescence images of A2780 and A2780/CP70-GFP co-culture 
spheroid.  A2780 spheroids had distinctly lower motility than spheroids of A2780/CP70-
GFP (CP70-GFP) cells.  This difference in motility is evident in the co-cultured spheroids 
due to preferential segregation between the two cell lines.  Motility determination of cell 
type in the MCI image was confirmed by fluorescence imaging. 
 
More recently, researchers in our group generated functional images of spheroid 
and biopsy samples (Figure 5.4) [151].  This involved separating the OCI capture 
sequence into 2 pixels by 2 pixels regions and generating a response spectrogram for each 
region.  The operator then selected a mask and threshold value based on features 
observed in the spectrograms to determine similarity of response.  Unfortunately, this 
method required the operator to inspect each spectrogram individually, 15625 
spectrograms for a standard 250 pixels by 250 pixels OCI image, and subjectively 






Figure 5.4. Functional images of selected spheroid and biopsy samples. 
 
For TDSI to become a practical imaging mode, a scriptable, standardized 
technique was needed to select tissue response features.  Feature vectors, as a way of 
condensing sample condition and response information, are a natural method for mapping 
regional responses within a tissue sample.  The standardized biomarkers recently adopted 
into BDI analysis protocol remove operator subjectivity and allow TDSI to be part of 
already existing BDI sample processing. 
 
5.3 Current Methodology 
5.3.1 Micro-spectrograms 
Micro-spectrograms are generated in a manner similar to traditional TDS (macro-) 
spectrograms (see CHAPTER 1.7), but the average spectra comprise response 
information from a few pixels instead of the entire OCI image.  A series of OCI images is 
acquired and divided into regions of regular pixel size.  The region size determines the 
granularity of the TDSI image.  An imaging target can be treated as a diffraction grating 




maximum spatial frequency  captured at the Fourier plane constrains the minimum 
resolvable feature, 
  5.1 
with a frequency grating spacing on the CCD of 
  5.2 
The field of view of the reconstructed image L relates to the grating spacing as 
  5.3 
which gives a the reconstructed image a pixel size p of  
  5.4 
This means that TDSI requires a minimum pixel size of 2 by 2 averaged OCI pixels to 
avoid oversampling the dynamic speckle. 
Once the OCI series is divided into pixel groups, normal TDS analysis occurs for 
each pixel during each image capture sequence in the series.  For an OCI image of N by 
N pixels, this results in a TDSI image of N/2 by N/2 pixels with each pixel having an 
associated backscatter brightness, NSD, and average fluctuation spectrum at each capture 
time.  A spectrogram for each pixel is generated by comparing the fluctuation spectrum at 
each time to the sample average baseline power spectrum.  Note that this baseline power 
spectrum is averaged across the entire sample, which modifies the interpretation of the 
micro-spectrograms to show how tissue behavior within a TDSI pixel compares to the 




CHAPTER 1.8) the BDI output of each TDSI pixel generates a feature vector that 
encapsulates the condition and response of the imaged tissue within that pixel.  Figure 5.5 
presents an illustration of the analysis flow. 
 
 
Figure 5.5. Illustration of TDSI image generation. 
 
5.3.2 Biomarker Maps and RGMerge 
Selected biomarkers are used as contrast agent to generate biomarker maps 
(Figure 5.6) that show regional differences in response amplitude for that biomarker.  
Individual maps are combined using a custom Matlab function called rgmerge.m that 
assigns one biomarker to the red value and another biomarker to the green value in a red-
green-blue (RGB) color space.  The result is an image (Figure 5.6) where the color of 
each pixel indicates how well the two biomarker maps overlap and color saturation 
indicates the strength of each biomarker.  Pixels look more red where the green-assigned 
biomarker has small values and look greener where the red-assigned biomarker has small 
values.  Where both biomarkers have large values the resulting pixel looks yellow, and 







Figure 5.6. Individual and merged biomarker maps of esophageal biopsy sample 
responding to carboplatin (25 μM) plus taxol (10 μM) combination therapy.  Maps use 
the values of ALLF and TANH biomarkers.  The merged image shows three regions with 
distinct response behavior: a central red region surrounded by a yellow region where both 
biomarkers overlap, and a small green region in the lower left of the image. 
 
Comparing two biomarkers of vastly different amplitudes resulted in merged 
TDSI images dominated by the biomarker with the largest value.  However, it was 
desirable to preserve some measure of the relative strength of biomarker, especially those 
relating to features of the spectrograms.  For this reason, conditional biomarker values 
(see CHAPTER 1.8) are scaled so that the largest negative value of each is -1 and the 
largest positive value is 1.  Response biomarkers are scaled together so that the largest 
negative value of all biomarkers is -1 and the largest positive value is 1.  Scaling 
maintains relative distance from zero so that values close to zero remain close to zero. 
Because rgmerge.m uses RGB color space, all values must be positive, which 
divides the biomarker space into positive and negative groups.  Representing the different 
possible combinations of positive and negative values for each pair of 82 biomarkers is 
challenging (Figure 5.7) and further research is required to devise a method that is both 






Figure 5.7. Example TDSI images of positive- and negative-value space combinations for 
two biomarkers.  Biomarker values are from an esophageal patient biopsy sample 
responding to carboplatin (25 μM) plus taxol (10 μM) combination therapy. 
 
5.4 Results 
5.4.1 Heterogeneity of tissue response for a single esophageal patient 
TDSI provides BDI a systematic method for visualizing the amount of 
heterogeneity present in a patient’s tumor. Figure 5.8 shows TDSI images for positive 
and negative biomarker combinations of nine selected biomarkers.  Color can be 
indicative of heterogeneous response, but because the data include positive and negative 





Figure 5.8. TDSI images for sample from a single esophageal biopsy patient.  ALLF (red) 
is compared against (green, from top to bottom) ST/2, TANH, SDIP, QDIP, Q3T/2, LOF, 
MID, and HIF.  Columns are positive- and negative-space combinations of each 
biomarker: (from right to left) positive red, positive green; negative red, negative green; 




We can classify patient sample heterogeneity by size and distinctness of regions 
into strong, moderate, and weak groups.  Samples 2, 5, 6, 7, 9, 13, and 15 show large, 
easily separable regions of different response and would be classified as strongly 
heterogeneous.  Samples 1, 3, 10, 11, and 16 show large bands of color, but those bands 
tend to be harder to separate and are classified as moderately heterogeneous. The 
remaining samples (4, 8, 12, and 14) show overlapping biomarker masks, or they 
exhibited generally weaker response and would be classified as weakly heterogeneous.  
Though subjective, this classification indicates that 75% of this patient’s samples exhibit 
strong to moderate heterogeneity.  Image segmentation methods are needed to make a 
more systematic assessment. 
 
5.4.2 Comparison of micro-spectrograms to macro-spectrogram  
TDSI shows differences in response that are masked in the macro-spectrogram 
and other BDI output.  These differences would confound response predictions and could 
lead to misapplication of chemotherapeutics, developments of drug-resistance, or later 
patient relapse.  Figure 5.9 shows BDI results for one esophageal patient biopsy sample 






Figure 5.9. BDI results for esophageal patient biopsy sample.  OCI and MCI images 
correspond to final observation of the sample following application of cisplatin (25 μM) 
plus fluorouracil (5fu, 25 μM) combination therapy.  The macro-spectrogram shows mild 
response to therapy.  The TDSI image has three regions: a central dark region, a green 
halo, and a red nodule in the upper left.  Micro-spectrograms for the three regions 
indicate that the green region experienced suppression in the low frequencies in response 
to therapy, while the red region experienced an enhancement.  The dark region (micro-
spectrogram not shown) showed a response similar to that indicated by the macro-
spectrogram. 
 
The OCI image for this sample shows no distinct tissue structures and is typical of 
biopsy samples.  The MCI image has a slight increase in motility visible in the upper 
right suggesting heterogeneous behavior, but the extent of the region is unclear.  The 
macro-spectrogram for this sample shows a slight overall suppression indicative of mild 




determine the size of the higher-motility region at the top-left of the MCI image.  TDSI 
also shows three regions within this sample.  When the micro-spectrogram of each region 
was plotted, the red region showed enhancement in the low- and mid-frequencies 
indicative of resistance to therapy, while the outer green region had suppression in those 
same frequency ranges, suggesting that a portion of the sample was more strongly 
responsive to therapy.  The central dark region had a micro-spectrogram similar to that of 
the macro-spectrogram.  When averaged during traditional TDS analysis, the responsive 
and resistive regional behaviors cancel out.  Therefore, while the macro-spectrogram 
would indicate mild response to therapy, portions of the patient’s cancer may be resistant 
and presage relapse and the development of completely a resistive cancer strain. 
 
5.5 Discussion and Conclusion 
Improvements in TDSI calculation allow for faster image generation, systematic 
biomarker selection, and lower operation interaction.  The analysis flow is 
complimentary to existing analysis methods, which saves computational time and data 
storage space. More research is needed, however, to find the best method for representing 
the information gained. 
Though only one experiment’s complete sample set is presented in this chapter, 
examples of heterogeneous response in TDSI images were not scarce among the sample 
sets processed so far.  Continuing research will develop objective methods for assessing 




patient’s biopsy.  Also, the addition of traditional imaging methods would illuminate the 
cause of heterogeneous response and help the project determine which biomarker 
combinations best differentiate tissue type.  
TDSI brings functional imaging to BDI analysis and opens new avenues of 
inquiry into how heterogeneous response may affect long-term patient survival.  Issues of 
representation and data compression must be addressed before the technique can be 
broadly applied to chemotherapeutic response tests.  However, initial results on 
esophageal patient biopsies are promising and indicate that heterogeneous structure is 
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Appendix A Biodynamic Study of Synergistic Effects in Pancreatic Tissue 
Synergistic effects play a critical role in the viability of potential cancer treatments 
because they potentially increase the effectiveness of the treatment while limiting the ill 
effect to the patient. Several studies in recent years have investigated different synergies, 
including between different chemotherapeutic drugs [152, 153], between 
chemotherapeutic drugs and different cancer treatments, and between different cancer 
treatments [18]. 
The research group of Dr. Melissa Fishel at the Indiana School of Medicine looked at 
synergistic effect of redox disruption with STAT3 blockade as a dual-targeted therapy for 
treating pancreatic ductal adenocarcinoma (PDAC) [154].  They showed that STAT3 is 
regulated by the redox function of the APE1/Ref-1 endonuclease and that the redox 
inhibitor E3330 blocked DNA binding of STAT3.  In cell culture assays, dual-targeted 
therapy using E3330 and the STAT selective inhibitor STATTIC synergized to inhibit 
growth and spread of PDAC cells with a 3-fold increase in inhibition over mono-
therapies of either E3330 or STATTIC.  However, because 2D cell cultures differ from 
3D tissue in both genetic expression and cellular environment, testing of this novel dual-
targeted therapy in 3D tissue models was needed. BDI is a natural response assay for 
testing combined STAT3/redox inhibition in 3D tissue. 
Cell cultures: MIA PaCa-2 cells were from American Type Culture Collection 
(ATCC) Manassas, VA. Cells were cultured in DMEM at 37 °C in a humidified CO2 
incubator.  All growth media contain 10% fetal calf serum (Atlanta Biologicals), 





Stat-inhibiting drugs: STATTIC and E3330 were provided by Dr. Mark Kelley, 
Indiana University School of Medicine. 
Sample preparation and imaging: The preparation and imaging methods for both 
tumor spheroid and cell suspension samples was the same as described in CHAPTER 2, 
with the following deviation: for tumor spheroids, 550 frames were captured at 25 frames 
per second instead of 500 frames.  This did not change the data analysis or workflow, 
however, as only 500 frames were used. 
Sample rejection protocol: Experiments exhibited several failure modes that caused 
samples to be rejected from the analysis. Samples would lose coherence-gaiting due to 
fringe washout, or would shift position due to immobilization failure. These modes 
showed strong changes in MCI compared with successful experiments (see Figure A.1a-
c).  Some samples showed erratic jumps in NSD without loss of coherence or 
immobilization (See Figure A.1d-e).  These modes were systematic failures that 
invalidated sample results. A few samples demonstrated an unusually strong response to 
STATTIC, either alone or in combination with E3330. These pathological cases were 
marked by a strong decrease in normalized standard deviation of the speckle intensity and 
by strong shifts in the tissue response spectrograms (See Figure A.1f-g). It was not 
possible a priori to determine when a sample would have a pathological response.  The 
reason for such a response is unknown. These samples were not included in the 
combinatorial response calculations described below.  An entire experiment was rejected 







Figure A.1. Examples of accepted and rejected samples.  Individual samples were 
rejected because of coherence-gate loss (a) or immobilization failure (b) after adding drug. 
Acceptable MCI behavior is shown in (c).  Some samples showed normal acceptable 
MCI, but had erratic jumps in NSD (d). Acceptable NSD behavior is shown in (e). Some 
samples exhibited pathological response (f) marked by clear changes in sample motility 
contrast, large decrease in NSD, and abnormally large change in power spectral density 
(spectrogram). Non-pathological behavior is shown in (g). 
 
Results: To study the combinatorial effects of kinase inhibitors on pancreatic cancer 
PaCa-2, we used BDI to see how the STAT-inhibitor STATTIC and the APE1-inhibitor 





controls were applied separately and in combination and tumor response was compared 
against negative controls (1.25 mM DMSO and growth medium).  Individual sample 
responses are shown in Figure A.2.  The average tumor response to each control is shown 
in Figure A.3. 
 
 
Figure A.2. Individual samples response spectrograms. 
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Figure A.3. Combinatorial averaged spectrograms. Spectrograms show average PaCa-2 
tumor response to the STAT-inhibitor drugs E3330, STATTIC, and their combination. 
Individual response spectrograms were calculated for each sample with the average 
negative control (DMSO) response of each data set subtracted from each sample in that 
set. Then the average response spectrogram over all data sets for each control was 
calculated. 
There is a visible enhancement of motion up to 0.5 Hz due to the addition of E3330 
and/or STATTIC. This enhancement is greater than any response to the DMSO in which 
both E3330 and STATTIC were dissolved. The average low-frequency enhancement was 
calculated beginning after 3.5 hours, which was the estimated half-max time of the 
response change. The results can be seen in Figure A.4. 
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Figure A.4. Percent change in low-frequency tumor response relative to DMSO. Shows 
the average change in power spectral density between 0 and 9 hours after a drug was 
applied.  
Discussion and Conclusion: Biodynamic imaging and analysis showed an 
enhanced effect in the combination therapy relative to the individual therapies.  However, 
the measured enhancement was not more than the sum of the individual effects of 
STATTIC and E3330, suggesting that the combination effects were additive and did not 
have any particular synergy when applied to 3D culture models. 
The cause of pathological response is unknown.  Several samples from at least 
two experimental sample groups exhibited an overwhelming sensitivity to applied 
therapy.  However, no experimental group showed pathological response in all samples 
indicating that this was a biological effect and not an artifact of the BDI system, nor due 
to operator error.  Even more intriguing was the fact that pathological behavior was not  
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isolated to the combination therapies, but also occurred in samples that received the 
mono-therapies.  More systematic investigation is needed before the cause of this 
hypersensitivity can be determined. 
. 
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Appendix B Assessing response to therapy for esophageal cancer patients using 
biodynamic imaging 
Patient biopsies: Esophageal patient biopsies were obtained from Indiana University 
Hospital.  Harvested tumors were placed in ice-cold media and were transported to John 
Turek’s laboratory within 2 hours and prepared for imaging.  Half the biopsy was 
immediately prepared while the other half was maintained at 4 °C for up to 36 hours 
before testing. Biopsies were sectioned using a razor blade to cut the tumor into pieces of 
approximately 1 mm3 in volume.  Pieces were affixed inside 96-well plates using a small 
drop of GLUture (Abbot Laboratories) and covered with agarose. Growth medium was 
added to each well. Experiments were performed immediately after plates were prepared. 
Chemotherapy drugs: Cisplatin, carboplatin, fluorouracil (5-FU), and paclitaxel 
(taxol) were obtained from Selleck Chemicals. Dimethyl sulfoxide (DMSO) came from 
Sigma-Aldrich. Drugs were prepared to twice the desired concentration to allow for later 
mixing inside the sample well.  Drug concentrations were as follows: 25 μM for cisplatin, 
carboplatin, and 5-FU; 10 μM for taxol.  DMSO dissolved in growth medium was used as 
the negative control in all experiments. DMSO was selected since it is the carrier for the 
other drugs before being added to growth medium to improve solubility.  
OCI sequence: A diagram and explanation of the OCI system is found in CHAPTER 
1.5.  OCI frames of each tumor section were captured in cycles every 40-48 minutes on 
average. Each capture sequence consisted of 15-45 seconds travel time to allow the 
system to transition between tumors, followed by frame capture: 10 background frames 
captured at 10 frames per second (fps) with the reference beam not zero-path matched, 
then 50 frames at 0.5 fps and 500 frames at 25 fps with the reference beam zero-path 
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matched.  Tumor sections were observed for 6 cycles (4.8 hours) to allow the samples to 
stabilize. Then half of the growth medium (~150 µL) was removed from each well and 
replaced with a drug at twice the intended concentration to limit disturbing the sample. 
Tumors were then observed for a further 12 cycles (9.6 hours). 
Results:  Figure B.1 shows average patient response to the mono- and combination 
therapies for esophageal patients 1-6.  Patients were designated as responsive or non-
responsive to therapy based on average therapy response spectrogram.  The response 
biomarkers were then clustered based on similarity within each population (Error! 
Reference source not found.Figure B.2). 
Figure B.1. Average response spectrograms for esophageal patients (#1-6).  The number 
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